

1 **Clinical Practice Guideline: Lymphedema**
 2
 3 **Date of Implementation: October 18, 2012**
 4
 5 **Product: Specialty**
 6

7
 8 **GUIDELINES**

9 **Medically Necessary**

10 American Specialty Health (ASH) considers complex lymphedema therapy (complete
 11 decongestive therapy) medically necessary for the treatment of intractable lymphedema
 12 when ALL of the following are met:

- 13 • Documented failure of a reasonable course of conservative medical management
 14 that includes home exercises, limb elevation, and compression garments.
- 15 • The lymphedema is directly responsible for impaired functioning in the affected
 16 limb.
- 17 • The complex lymphedema therapy is prescribed by or under the supervision of an
 18 appropriate healthcare provider.

19
 20 **Not Medically Necessary**

21 Vasopneumatic compression device use as part of complex lymphedema therapy is
 22 considered not medically necessary.

23
 24 Considered Medically Necessary when criteria in the applicable policy statements listed
 25 above are met:

26

CPT® Code	CPT® Code Description
97140	Manual therapy techniques (e.g., mobilization/manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes
97535	Self-care/home management training (e.g., activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes
29581	Application of multi-layer compression system; leg (below knee), including ankle and foot
25984	Application of multi-layer compression system; upper arm, forearm, hand, and fingers

HCPCS Code	HCPCS Code Description
S8430	Padding for compression bandage, roll
S8431	Compression bandage, roll
S8950	Complex lymphedema therapy, each 15 minutes

1
2 Multi-layered, sustained, graduated, high compression bandage systems (CPT code 29581-
3 Application of multi-layer compression system; leg (below knee), including ankle and foot
4 and CPT code 29584 - Application of multi-layer compression system; upper arm, forearm,
5 hand, and fingers) are used primarily to treat lymphedema and venous or stasis ulcers. A
6 number of graduated, high-compression bandage systems products have been developed,
7 including Profore[®], Dyna-Flex[®], Surepress[®], Setopress[®], and other similar product
8 systems.

9
10 Providers should note that the treatment of lymphedema with the application of high
11 compression bandage systems continues to be non-covered by Medicare. However, a brief
12 period, i.e., three or fewer sessions if no new specific issues are identified, of patient and/or
13 caregiver education for home management of lymphedema with compression wrap
14 applications may be medically necessary and reimbursable. Medical necessity for the
15 education must be clearly indicated in the patient's record and must meet the code
16 descriptor requirements for CPT 97535, supporting home management training. S8430 –
17 padding for compression bandage, roll and S8431 – compression bandage, roll may be
18 appropriate and allowable per health plan benefit.

19 DESCRIPTION

20
21 Complex lymphedema therapy (CLT) is a non-invasive treatment for lymphedema with the
22 aim to reduce and control the amount of swelling in the affected limb and restore function.
23 Complex lymphedema therapy (CLT) is a noninvasive treatment that is a considered a
24 standard of care for lymphedema. This method has also been referred to as complete
25 decongestive physiotherapy (CDP), and complex decongestive therapy (CDT). The
26 treatment aim is to reduce and control the amount of swelling in the affected limb and
27 restore function. The objective of the technique is to redirect and enhance the flow of lymph
28 through intact cutaneous lymphatics. Programs are generally provided on an outpatient
29 basis in the office setting or in a lymphedema rehabilitation center or clinic (Lasinski and
30 Boris, 2002; MacDonald et al., 2003). The typical CLT program consists of two phases of
31 treatment: a treatment phase and a maintenance phase. Phase I, the treatment phase, usually
32 last 2 to 4 weeks. This phase consists of four components (Lawenda et al., 2009):

- 33 • Skin and nail care: The purpose is to inspect skin, provide moisture and prevent
34 infection.

- 1 • Manual lymph drainage (MLD): This is a light, massage-like technique that is
- 2 performed for 30-60 minutes and is used to stimulate residual lymphatic vessels to
- 3 carry excess fluid from the affected extremity.
- 4 • Compression bandaging: This involves wrapping multi-layered bandages around
- 5 affected limb.
- 6 • Therapeutic exercise: This includes movement of the limb through a range of
- 7 motion with bandaging in place.
- 8

9 Most patients will be able to progress to a home-based, self-managed program after an
 10 initial in-office program of 1–2 weeks. Instruction in self-management should begin in the
 11 first week of therapy. Both patients and family are taught bandaging and exercise
 12 techniques, as well as the essentials of skin and nail care. After the initial one- to two-week
 13 program, patients should be re-evaluated to determine whether continued in-office therapy
 14 is necessary or if treatment can be provided in the home.

15
 16 Phase II, the maintenance phase, consists of life-long self-care to maintain the size of the
 17 limb. In this phase, the patient maintains and optimizes the results by applying the
 18 techniques learned in the treatment phase including skin and nail care, wearing an elastic
 19 sleeve during the day, bandaging the affected limb overnight and exercises (Petrek, 2000).

20 21 **Duration and Frequency**

22 A program of complex lymphedema therapy provided 2–5 times per week for two weeks
 23 is generally considered medically necessary for the treatment of primary or secondary
 24 lymphedema, in the absence of any contraindications. Programs that go beyond a four-
 25 week period are generally considered not medically necessary.

26 27 **Contraindications**

28 Absolute contraindications to lymphedema therapy include:

- 29 • Acute infections of the affected limb
- 30 • Venous or arterial obstruction (deep vein thrombosis)
- 31 • Active malignancy confirmed or suspected local disease
- 32 • Unwillingness or inability of the member to participate in the treatment
- 33

34 Relative contraindications to lymphedema therapy include:

- 35 • Suspicion of deep vein thrombosis prior to starting treatment
- 36 • Congestive heart failure
- 37 • When the local massage is performed in area of irradiated soft tissue
- 38

39 **GENERAL BACKGROUND**

40 Lymphedema is defined as the excessive and persistent accumulation of protein rich fluid
 41 that collects in the interstitial spaces, due to an inefficiency of the lymphatic system (Szuba
 42 et al., 2002; Leal et al., 2009). Lymphedema occurs primarily as a result of malformation,

1 underdevelopment, or acquired disruption of the lymphatic circulation (Szuba et al., 2002).
2 Primary lymphedema is due to congenital defects of the lymphatic system, which can affect
3 from one to as many as four limbs or other parts of the body and is considered rare (National
4 Lymphedema Network, 2011). Secondary lymphedema is acquired and is due to an
5 obstruction or interruption in the lymphatic circulation. Secondary lymphedema can
6 develop as a result of surgery, radiation, infection or trauma. It is a common treatment-
7 related side effect experienced by cancer patients. Patients that undergo surgery for breast
8 cancer that includes node dissection or axillary radiation therapy are at high risk of
9 developing lymphedema.

10
11 Historically, lymphedema has been classified into three (3) stages based on its severity and
12 on observation of the patient's condition. Currently, the International Society
13 of Lymphedema is recognizing a Stage 0 in patients, which refers to a latent or sub-clinical
14 condition where swelling is not evident despite impaired lymph circulation. Patients often
15 report a feeling of heaviness in the limb; however, many patients are asymptomatic in the
16 latency stage. Stage 0 may be present for months or years prior to a patient exhibiting signs
17 and symptoms of edema. Stage I lymphedema is referred to as spontaneously reversible
18 lymphedema (Lawenda et al., 2009; Bicego et al., 2006) and typically involves pitting
19 edema, an increase in limb girth (usually upper extremity), and heaviness. Stage II is also
20 known as spontaneously irreversible lymphedema and it is marked by spongy consistency
21 of the tissue and non-pitting edema (Bicego et al., 2006). Tissue fibrosis marks the
22 beginning of hardening of the limbs and increased girth of extremity and is often found in
23 Stage II (Bicego et al., 2006). Stage III is the most advanced stage and is often referred to
24 as lymphostatic elephantiasis. During Stage III the swelling is irreversible with tissue being
25 fibrotic and unresponsive including patients who present with very large limb(s) size. It is
26 associated with a significant increase in the severity of the fibrotic response, tissue volume,
27 and other skin changes such as papillomas, cysts, fistulas, and hyperkeratosis (Lawenda et
28 al., 2009; Zuther, 2005). With regards to Stage 0, the literature is insufficient to conclude
29 that the use of CDT is either clinically effective or ineffective in the treatment of subclinical
30 or latent stage of breast cancer related lymphedema.

31
32 The best practice or gold standard for lymphedema treatment is considered CDT,
33 also known as complex lymphedema therapy (CLT). CDT is a noninvasive treatment and
34 consists of four basic components as follows: skin and nail care, manual lymph drainage
35 (MLD), followed by bandaging/compression, education, and exercise. The goal of CDT is
36 to reduce and control the amount of swelling in the affected limb and restore function.
37 A treatment option that may be used to manage secondary lymphedema is intermittent
38 pneumatic compressions (IPC) (vasopneumatic compression) which is often added to
39 CDT. However, evidence does not support the addition of IPC to CDT or within any
40 treatment plan. Low-level laser therapy (LLLT) is another treatment option that has
41 been studied as a treatment when used in conjunction with other standard lymphedema
42 treatments. However, low-level laser is currently considered experimental, investigational

1 and/or unproven. Exercise demonstrates improvements in function and quality of life
 2 (QoL), but not in limb reduction. The goal of all conservative treatment is to reduce and
 3 control the amount of swelling in the affected limb and restore function.

4 **EVIDENCE REVIEW**

6 Lymphedema is a common sequela of cancer or its treatment that affects the lymphatic
 7 transport system that results in failure of lymph node drainage. Secondary lymphedema is
 8 often a debilitating, chronic, progressive condition that commonly occurs after treatment
 9 of breast cancer. A number of health professional and patient instigated conservative
 10 therapies have been developed to help treat this condition. A systematic review
 11 conducted by Moseley et al. (2007) reviewed the common conservative therapies used
 12 for management of secondary arm lymphedema as follows: complex physical
 13 therapy, manual lymphatic drainage, pneumatic pumps, oral pharmaceuticals, low level
 14 laser therapy, compression bandaging and garments, limb exercises and limb
 15 elevation. This study found that the more intensive and health care professional driven
 16 therapies, such as complex physical therapy (skin and nail care, manual lymphatic
 17 drainage, a multilayer compression bandage and therapeutic exercises), manual lymphatic
 18 drainage, pneumatic pump and laser level light therapy generally yielded the greater
 19 volume reductions, compared to self-instigated therapies such as compression garment
 20 wear, exercises and limb elevation. These self-care methods showed reductions, however
 21 in lesser volumes. All conservative therapies reviewed in this study produced
 22 improvements in subjective arm symptoms and QoL issues, where these were measured.

24 Stout et al. (2008) completed a study on Stage 0 lymphedema. They used infrared
 25 optoelectronic technology to identify those at risk for edema based on volume
 26 measurements. This technology allows for changes to be noted before they are actually
 27 visible to the eye. When these changes are noted, treatment initiated immediately may
 28 prevent the development of further stages of lymphedema. However, there is no standard
 29 for the treatment of early-stage, subclinical lymphedema. When the diagnosis of breast
 30 cancer related lymphedema is delayed, therapeutic management requires intensive
 31 decongestive therapy and life-long maintenance. This study suggested that an early
 32 intervention protocol with 20- to 30-mm Hg compression garments, significantly reduced
 33 the affected limb volume to near baseline measures and prevented progression to a more
 34 advanced stage of lymphedema for at least the first year postoperatively. Further research
 35 is warranted to confirm the long-term clinical and cost effectiveness of this early
 36 intervention model compared with a traditional model in treating breast cancer related
 37 lymphedema.

39 **Complete Decongestive Therapy (CDT), Manual Lymphatic Drainage (MLD), and** 40 **Compression Methods**

41 A prospective trial of complete decongestive therapy for upper extremity lymphedema after
 42 breast cancer was reviewed by Mondry et al. (2004). Patients completed two to four (2-4)

1 weeks (median, 2 weeks) of treatment; including skin and nail care, manual
2 lymphatic drainage, a multilayer compression bandage and therapeutic exercises. Edema
3 of the affected limb was reassessed on a weekly basis. Authors concluded that decreasing
4 girth correlated significantly with decreasing visual analogue scale scores for pain, but
5 not with increasing QoL. Data gathered showed median girth reduced 1.5 cm and median
6 volume reduced 138mL. This study concluded that compliance with the treatment regimen
7 at home decreased with duration of the program and girth reductions contributed to less
8 pain. Increased frequency of treatment sessions provides marked improvement in girth,
9 volume, and weight but resulted in poorer compliance. Longer latency more
10 successfully reduces girth, volume, and pain and increases QoL. Pain and QoL are
11 improved by treatment and continue to improve after treatment has ended. A randomized
12 controlled trial conducted by McNeely et al. (2004) looked at the addition of manual lymph
13 drainage to compression therapy for managing breast cancer-related lymphedema. The
14 authors of this study compared the reduction in arm lymphedema volume achieved from
15 manual lymph drainage massage in combination with multi-layered compression
16 bandaging to that achieved by compression bandaging alone. Treatment group one
17 received manual lymph drainage (MLD)/compression bandaging (CB). This group
18 received 45 minutes of daily MLD and CB, Monday-Friday for four (4) weeks. The second
19 treatment group received short stretch bandaging, Monday-Friday for four (4) weeks.
20 Authors concluded that a significant reduction in lymphedema volume was found over the
21 four (4) week period for both the manual lymph drainage/compression bandaging and
22 compression bandaging alone groups. No significant differences existed between
23 groups (McNeely et al., 2004).

24
25 Koul et al. (2007) assessed the results of combined decongestive therapy and manual
26 lymphatic drainage in patients with breast cancer-related lymphedema over a two-year
27 period. This study was a non-randomized clinical trial that reviewed data from 250 patients
28 with a final analysis reviewed from 138 patients. The pre- and post-treatment volumetric
29 measurements were compared and correlated with age, body mass index, and type of
30 surgery, chemotherapy, and radiotherapy. One group was treated with all four (4) parts of
31 combined decongestive therapy for one (1) hour daily for up to several weeks, depending
32 on the severity and response. Combined decongestive therapy consisted of manual
33 lymphatic drainage, compression, exercises for the arm and shoulder, and deep breathing
34 to help promote venous and lymphatic flow. Patients were also fitted with custom-
35 made garments to be worn daily while awake and removed at bedtime. Self-lymph drainage
36 at least once daily was also recommended. A second treatment group received MLD
37 alone. They were also fitted for custom compression garments. Self-lymph drainage was
38 also recommended. A third treatment group received one hour of home instruction and
39 counseling, including simple self-drainage techniques, skin care, and exercise. They also
40 received custom compression garments. Results noted a significant reduction in arm
41 volumes at one (1) year after the beginning of treatment with some or all components of
42 combined decongestive therapy in patients with lymphedema after breast cancer treatment.

1 Patients with moderate to severe lymphedema had a maximal response after combined
2 decongestive therapy, and patients enrolled in the home program had mild lymphedema
3 and less dramatic responses to treatment. Authors concluded that combined
4 decongestive therapy and manual lymphatic drainage with exercises were associated with
5 a significant reduction in the lymphedema volume in all groups assessed. Long-term
6 management of breast cancer-related lymphedema after intensive decongestive therapy
7 was studied by Vignes et al. (2007). The authors' aim was to describe the effect of the
8 maintenance therapy on lymphedema volume reduction and to analyze the impact of the
9 different components of treatment in women with upper limb lymphedema after breast
10 cancer treatment. The treatment consisted of an intensive phase of CDT, including manual
11 lymph drainage (30 minutes, five [5] times a week), low stretch compression bandaging
12 (24 hours daily), exercises after bandages were applied to enhance lymphatic flow from
13 peripheral to central compartments and skin care. Maintenance therapy consisted
14 of education (3 bandages per week). Authors concluded that bandaging and elastic
15 sleeves are a key component to maintenance therapy after intensive CDT.

16
17 A systematic review was conducted by Karki et al. (2009) on the effects and harms of
18 physiotherapy methods of lymphedema therapy in breast cancer patients. Fourteen
19 randomized controlled studies were included, two of which had moderate risk of bias and
20 the remainder had high risk. There was moderate evidence that compression bandages
21 alone decreased lymphedema, and that pneumatic pumps had no effect on
22 lymphedema compared to no treatment. With the remainder of the studies that had high
23 risk of bias, the interventions and comparisons varied across all trials. This review found
24 moderate evidence to support that compression bandages decreased lymphedema.
25 There was no evidence regarding volume reduction outcomes in any other body part
26 except the upper limb. Evidence on other physiotherapy methods and combinations is
27 limited due to poor quality of the studies. Devoogdt et al. (2010) conducted a systematic
28 review of combined physical therapy, intermittent compression and arm elevation for
29 treatment of lymphedema secondary to axillary dissection for breast cancer. The review
30 included ten randomized controlled trials and non-randomized, experimental trials. The
31 review found that combined physical therapy can be considered as an effective treatment
32 modality for treatment of lymphedema; however, the effectiveness of its different
33 components remains uncertain. Szolnoky et al. (2009) compared manual lymphatic
34 drainage with manual lymphatic drainage plus intermittent pneumatic
35 compression for treatment of unilateral arm lymphedema in 27 women previously
36 treated for breast cancer. One treatment group received complex decongestive
37 physiotherapy (CDP), which included manual lymph drainage (MLD) using the Vodder
38 technique. Treatment sessions were for 60 minutes per day for 10 consecutive business
39 days by a specific physiotherapist, followed by skin care, bandaging, and exercise. MLD
40 was performed on the neck, breast, and abdomen. The second treatment group received
41 complex decongestive physiotherapy plus intermittent pneumatic compression
42 (CDP+IPC). This included the same MLD using the Vodder technique for 30 minutes

1 per day for 10 days, followed by 30 minutes of IPC with a Lympha Mat device at a pressure
 2 of 50 mmHg. Patient also received skin care, bandaging, and exercise. Each treatment
 3 method was effective in reducing limb size, but the combination treatment of
 4 CDP+IPC showed statistically significant greater reductions in limb size when compared
 5 to CDP alone, with no negative side effects noted. No other statistically significant changes
 6 were noted in the patients' subjective reports with either treatment method at any time.

7
 8 A technology assessment requested by Centers for Medicare and Medicaid Services (CMS)
 9 was conducted by McMaster University Evidence-based Practice Center for the Agency
 10 for Healthcare Research and Quality (AHRQ) (Oremus et al., 2010) diagnosis and
 11 treatment of secondary lymphedema. The review included randomized controlled trials or
 12 observation studies with comparison groups (e.g., cohort, case control). The assessment
 13 concluded the following:

- 14 • CDT has been observed to have a significant effect on edema reduction and is
 15 recognized internationally as a successful treatment for lymphedema.
- 16 • There is no single treatment that is considered usual care for lymphedema. At this
 17 time, CDT, which is a combination of therapies, is suggested as the main method
 18 of conservative care for lymphedema. CDT includes manual lymphatic drainage
 19 (MLD), application of compression low stretch bandages, exercise and skin care.

20
 21 A randomized controlled-group study conducted by Kim et al. (2010) investigated the
 22 differences between the effects of complex decongestive physiotherapy with and without
 23 active resistive exercise for the treatment of patients with breast cancer-related
 24 lymphedema. Treatment group one received CDT (manual lymphatic
 25 drainage, compression therapy, and exercise, including resistance training) five (5) times
 26 a week for two weeks followed by self-administered treatment for another six weeks. The
 27 control group received the CDT without the resistance training added to the exercise
 28 program. Authors concluded that active resistive exercise with CDT did not create
 29 additional swelling and assisted with reduction of arm volume. QoL was also improved
 30 for this group. The National Lymphedema Network (NLN) published a position statement
 31 regarding treatment of lymphedema (NLN, 2011). Included in the document were the
 32 following statements regarding CDT:

- 33 • CDT is the main treatment for lymphedema. Experts who treat lymphedema
 34 consider CDT the “gold standard” of treatment. The treatment has been shown to
 35 be safe and effective. CDT is the current international standard of care for managing
 36 lymphedema.
- 37 • CDT has been shown to be effective in large numbers of case studies demonstrating
 38 limb volume reductions of 50–70% or more, improved appearance of the limb,
 39 reduced symptoms, improved quality of life, and fewer infections after treatment.
 40 Even people with progressive lymphedema for 30 years or more before starting
 41 CDT have been shown to respond.
- 42 • Patient adherence during Phase II CDT is critical for preserving volume reduction.

- It is recommended that CDT adaptations or other lymphedema treatments be used on a case-by-case basis under the supervision of a healthcare provider (e.g., physician, nurse, physician assistant, therapist) with demonstrated expertise in lymphedema management.

In 2020, the International Society of Lymphology (ISL) published an updated consensus document regarding the diagnosis and treatment of peripheral lymphedema (ISL, 2020). The document makes the following notes regarding lymphedema treatment:

- CDT is included in the statement as a standard treatment for lymphedema that is backed by longstanding experience. The first phase includes skin care, light manual massage, range of motion exercise and compression with multilayered bandage-wrapping. The second phase aims to conserve and optimize results obtained in Phase 1.
- An assessment should be made of limb volume before, during and after treatment. Treatment outcomes should be reported in a standardized manner in order to assess effectiveness of treatment protocols.

Hwang et al. (2013) completed a systematic review and meta-analysis on the effects of MLD on breast cancer-related lymphedema. They investigated whether manual lymphatic drainage (MLD) could prevent or manage limb edema in women after breast-cancer surgery. In total, 10 RCTs with 566 patients were identified. Authors concluded that the current evidence from RCTs does not support the use of MLD in preventing or treating lymphedema. However, clinical and statistical inconsistencies between the various studies confounded our evaluation of the effect of MLD on breast-cancer-related lymphedema. Lasinski (2013) summarized the evidence on the management of lymphedema and provided recommendations. CDT is effective in reducing lymphedema, although the contribution of each individual complete decongestive therapy component has not been determined. In general, levels of evidence for complete decongestive therapy are moderate. Fu et al. (2014) aimed to provide healthcare professionals with evidence-based clinical practice guidelines for lymphedema treatment and management through a systematic review. Findings of the systematic review support complete decongestive therapy, compression bandages, and compression garments with highest evidence for best clinical practice. Weight management, full-body exercise, education, prevention, and early intervention protocols are likely to be effective for clinical practice.

Shao et al. (2014) sought to determine whether the use of an intermittent pneumatic pump (IPC) could manage lymphedema effectively. Seven randomized controlled trials, with 287 patients, were included. Results showed that the use of the IPC could alleviate lymphedema, but no significant difference between routine management of lymphedema with or without pneumatic pump existed. Authors concluded that current trials fail to show the effectiveness of the addition of an IPC to the routine management of BCRL. Leung et al. (2015) evaluated the available evidence for the treatment of secondary lower limb

1 lymphoedema in patients with malignancies. Authors concluded that few studies have
2 evaluated the clinical effectiveness and potential side effects of treatments for lower limb
3 lymphoedema. Moreover, symptoms and quality-of-life assessments were inconsistently
4 reported. All included studies report lower limb volume reduction after treatment, which
5 includes complex decongestion therapy, graded compression stockings and lymphovenous
6 microsurgical shunts. Adequately powered randomized controlled trials of these
7 interventions are recommended. Ezzo et al. (2015) assessed the efficacy and safety of MLD
8 in treating BCRL. Six trials were included. Authors concluded that MLD is safe and
9 may offer additional benefit to compression bandaging for swelling reduction.
10 Compared to individuals with moderate-to-severe BCRL, those with mild-to-
11 moderate BCRL may be the ones who benefit from adding MLD to an intensive
12 course of treatment with compression bandaging. This finding, however, needs to be
13 confirmed by randomized data. In trials where MLD and sleeve were compared with a non-
14 MLD treatment and sleeve, volumetric outcomes were inconsistent within the same trial.
15 Findings were contradictory for function (range of motion), and inconclusive for quality of
16 life. For symptoms such as pain and heaviness, 60% to 80% of participants reported feeling
17 better regardless of which treatment they received. One-year follow-up suggests that once
18 swelling had been reduced, participants were likely to keep their swelling down if they
19 continued to use a custom-made sleeve. Finnane et al. (2015) sought to summarize efficacy
20 findings of reviews on lymphedema treatment. Overall, there was wide variation in review
21 methods. The quality of studies included in reviews, in study design and reporting
22 overall, has been poor. Reviews consistently concluded that complex physical therapy is
23 effective at reducing limb volume. Volume reductions were also reported after the use of
24 compression garments, pumps, and manual lymphatic drainage. However, greatest
25 improvements were reported when these treatments formed a combined treatment
26 program. Large, well-designed, evaluated, and reported randomized, controlled trials are
27 needed to evaluate and compare treatments.

28
29 Elastic therapeutic taping (e.g., Kinesio taping) has been proposed as a treatment
30 intervention for lymphedema, given its properties and hypothesized mechanism to lift the
31 skin away from the adjacent muscle and allow intercellular fluid to flow more freely. For
32 example, lymph will move more easily out of lymph channels and into larger lymph ducts
33 for uptake. Bialoszewski et al. (2009) studied the effects of KT in reducing edema of lower
34 limbs in patients subjected to limb lengthening. Twenty-four (24) patients developed post-
35 surgical lymphedema. They were randomized into two (2) groups. One group received
36 taping and the other received standard physiotherapy (lymphatic drainage). Both methods
37 reduced edema significantly pre- and post-treatment (after 10 days); however, the
38 application of the KT produced a significantly faster reduction of edema compared to
39 standard lymphatic drainage methods. A study by Tsai et al. (2009) hypothesized whether
40 KT could replace the bandage in decongestive lymphatic therapy (DLT) for breast-cancer-
41 related lymphedema. The pilot study looked at standard DLT combined with pneumatic
42 compression (PC) or modified DLT using KT combined with PC; both types of treatments

1 resulted in reduced girth measurements of the upper extremity and other outcomes in forty-
 2 one (41) patients with breast-cancer-related lymphedema. Results demonstrated no
 3 significant differences between the two types of treatments. Thus, use of KT could replace
 4 the bandage typically used in DLT. Morris et al. (2013) reported on a systematic review
 5 with the purpose of this study was to investigate the effect of Kinesio Tex tape (KTT) from
 6 randomized controlled trials (RCTs) in the management of clinical conditions. The review
 7 included eight RCTs: six included patients with musculoskeletal conditions; one with
 8 breast-cancer-related lymphedema; and, one included stroke patients with muscle
 9 spasticity. Six studies included a sham or usual care tape/bandage group. The review found
 10 limited to moderate evidence that KTT is no more clinically effective than sham or usual
 11 care tape/bandage. The authors concluded that there currently exists insufficient evidence
 12 to support the use of KTT over other modalities in clinical practice. Kalron and Bar-Sela
 13 (2013) reported on a systematic review that assessed the effects of therapeutic Kinesio
 14 Taping (KT) on pain and disability in participants suffering from musculoskeletal,
 15 neurological and lymphatic pathologies. Twelve met inclusion criteria. The final 12 articles
 16 were subdivided according to the basic pathological disorders: musculoskeletal ($N=9$) (four
 17 randomized, controlled trials (RCT), three single-blinded RCT, one cross-over trial and
 18 one case-control study); neurological ($N=1$) (RCT); and, lymphatic ($N=2$) (RCT).
 19 Regarding lymphatic disorders, inconclusive evidence was reported. The authors
 20 concluded that although KT has been shown to be effective in aiding short-term pain, there
 21 is no firm evidence-based conclusion of the effectiveness of this application on the majority
 22 of movement disorders within a wide range of pathologic disabilities. Gatt et al. (2017)
 23 aimed to determine the effectiveness and safety of kinesiotope (KT) in the management
 24 of cancer-related lymphoedema (CRL) compared to compression bandaging or hosiery.
 25 Five studies were included in the meta-analysis of the primary outcome limb volume ($n =$
 26 203 , KT $n = 91$, compression $n = 112$). No significant difference existed between the
 27 interventions. An increased risk of skin complications with KT was reported in five studies
 28 affecting between 10% and 21% of patients. Where lymphoedema-related symptoms
 29 were reported KT was found to be superior to compression. Paradoxically,
 30 patients receiving bandaging reported a higher QoL. Thus, authors concluded that
 31 KT was not found to be more comfortable than bandaging and should only be used with
 32 caution where bandaging cannot be used.

33
 34 Torres-Lacomba et al. (2020) compared the effects of four types of bandages and kinesio-
 35 tape and determine which one is the most effective in women with unilateral breast cancer-
 36 related lymphoedema. A total of 150 women presenting breast-cancer-related
 37 lymphoedema were randomized into five groups ($n = 30$). All women received an intensive
 38 phase of complex decongestive physiotherapy including manual lymphatic drainage,
 39 pneumatic compression therapy, therapeutic education, active therapeutic exercise and
 40 bandaging. The only difference between the groups was the bandage or tape applied
 41 (multilayer; simplified multilayer; cohesive; adhesive; kinesio-tape). The main outcome
 42 was percentage excess volume change. Other outcomes measured were heaviness and

1 tightness symptoms, and bandage or tape perceived comfort. Data were collected at
2 baseline and finishing interventions. This study showed significant differences between the
3 bandage groups in absolute value of excess volume. The five groups exhibited a significant
4 decrease in symptoms after interventions, with no differences between groups. In addition,
5 kinesio-tape was perceived as the most comfortable by women and multilayer as the most
6 uncomfortable ($P < 0.001$). The most effective were the simplified multilayer and the
7 cohesive bandages. The bandages/tape with the least difference were kinesio- and adhesive
8 bandage.

9
10 Zasadzka et al. (2018) compared the effectiveness of multi-layer compression
11 bandaging (MCB) and CDT for treating lymphedema in elderly patients. One
12 hundred three patients (85 women and 18 men) aged ≥ 60 years, with unilateral lower
13 limb lymphedema. The subjects were divided into two groups: 50 treated with CDT
14 and 53 with MCB. Pre- and post-treatment BMI, and average and maximum
15 circumference of the edematous extremities were analyzed. Results noted a reduction
16 in swelling in both groups was achieved after 15 interventions. Both therapies
17 demonstrated similar efficacy in reducing limb volume and circumference, but MCB
18 showed greater efficacy in reducing the maximum circumference. Authors concluded
19 that compression bandaging is a vital component of CDT. Maximum lymphedema
20 reduction during therapy and maintaining its effect cannot be achieved without it.
21 Sezgin Ozcan et al. (2018) evaluated the effects of CDT on upper extremity
22 functions, the severity of pain, and quality of life. A total of 37 women with breast
23 cancer-related lymphedema (BCRL) [age, 53.6 ± 11.2 (28-72)] were included in this
24 study. All patients underwent CDT-phase 1 program, including meticulous skin care,
25 manual lymphatic drainage, remedial exercises, and compression bandages. The
26 mean of the posttreatment volume of the affected limb was lower compared to
27 pretreatment volume. A statistically significant reduction in pain and heaviness VAS
28 scores and improvement of shoulder mobility among upper extremities with
29 lymphedema ($p < 0.001$) was noted after CDT. The mean of posttreatment DASH
30 score was lower, and all subgroups of the SF-36 parameters were increased after the
31 CDT application. Also, being under 65 years old, having a body mass index above
32 30 and short duration of lymphedema were found to be related to greater
33 improvement in upper extremity functions. Authors concluded that CDT provides
34 enhancement of upper extremity functions and quality of life in patients with BCRL.

35
36 Michopoulos et al. (2020) evaluated the effectiveness and safety of CDT of phase I in the
37 Greek population with lymphedema. CDT was implemented in all patients for 20 sessions
38 in a four-week treatment period. The edema's (excess volume (EV) and percent of excess
39 volume (PEV)) measurements were carried out four times in the treatment period, whereas
40 the percent reduction of excess volume (PREV) was calculated at the end of phase I. Every
41 infection, trauma of skin, and pain of limb during the treatment was also recorded. One-
42 hundred five patients with lymphedema were enrolled, of whom 31.4% had upper limb

1 lymphedema and 68.6% had lower limb lymphedema. A significant reduction between the
 2 pre-treatment and post-treatment values of EV and PEV was found for both upper and
 3 lower limb lymphedema. For patients with upper limb lymphedema, the average PREV
 4 was 66.5%, whereas for patients with lower limb lymphedema, a 71.5% median value was
 5 measured. No side effects from the treatment were recorded during CDT. Authors
 6 concluded that the proper treatment of the CDT phase I ensures safety and a great reduction
 7 in edema in patients with lymphedema that predispose the success of phase II of CDT.

8
 9 Watanabe et al. (2019) authored an article on the development and themes of diagnostic
 10 and treatment procedures for secondary leg lymphedema in patients with gynecologic
 11 cancers. They note that for the treatment of lymphedema, complex decongestive
 12 physiotherapy (CDP) including manual lymphatic drainage (MLD), compression therapy,
 13 exercise and skin care, are generally performed. In recent years, CDP has often required
 14 effective multi-layer lymph edema bandaging (MLLB) or advanced pneumatic
 15 compression devices (APCDs). If CDP is not effective, microsurgical procedures can be
 16 performed. They conclude that the most important concern is the prevention of secondary
 17 lymphedema, which is achieved through approaches such as skin care, weight control,
 18 gentle limb exercises, avoiding sun and heat, and elevation of the affected leg.

19
 20 In accordance with the most recent Consensus Document of the International Society of
 21 Lymphology (2020), CDT should include two phases: 1. Phase I: characterized by skincare,
 22 manual lymphatic drainage (MLD), with or without deeper techniques including muscle
 23 pumping exercises or hydraulic pressotherapy, followed by multilayer compression
 24 bandage, aiming at improving lymphedema volume; 2. Phase II: characterized by skincare
 25 and compression garments wearing, including lowstretch elastic stocking or sleeve, aiming
 26 at avoiding complications and conserving the results obtained in Phase I.

27
 28 Thompson et al. (2021) evaluated the effectiveness of MLD for those at-risk of or living
 29 with lymphedema. Seventeen studies with a total of 867 female and two male participants
 30 were included. Only studies examining breast cancer-related lymphedema were identified.
 31 Some studies reported positive effects of MLD on volume reduction, quality of life and
 32 symptom-related outcomes compared with other treatments, while other studies reported
 33 no additional benefit of MLD as a component of complex decongestive therapy. In patients
 34 at-risk, MLD was reported to reduce incidence of lymphedema in some studies, while
 35 others reported no such benefits. Authors concluded that reviewed articles reported
 36 conflicting findings and were often limited by methodological issues. They suggest the
 37 need for further experimental studies on the effectiveness of MLD in lymphedema. There
 38 is some evidence that MLD in early stages following breast cancer surgery may help
 39 prevent progression to clinical lymphedema. MLD may also provide additional benefits in
 40 volume reduction for mild lymphedema. However, in moderate to severe lymphedema,
 41 MLD may not provide additional benefit when combined with complex decongestive
 42 therapy.

1 Kalemikerakis et al. (2021) authored an article on the diagnosis and management of cancer-
2 related lymphedema. They note that early diagnosis and treatment of lymphedema is
3 related with better therapeutic outcomes. Women with breast cancer confront more
4 problems with lymphedema than with mastectomy. Its effect on patients' quality of life is
5 relevant to changes in body image, self-esteem, feelings of weakness, fear and anxiety
6 about disease progression, financial costs, and reduced limb function. Relative to
7 conservative management, authors summarize that CDT remains the treatment of choice
8 and in combination with exercise, weight control programs and self-care training seems to
9 significantly improve patients' quality of life. Forner-Cordero et al. (2021) assessed
10 whether treatment with intermittent pneumatic compression plus multilayer bandages is
11 not inferior to classical trimodal therapy with manual lymphatic drainage in the
12 decongestive lymphedema treatment. 194 lymphedema patients, stage II-III with excess
13 volume > 10% were stratified within upper and lower limb and then randomized to one of
14 the three treatment groups. Baseline characteristics were comparable between the groups.
15 For interventions all patients were prescribed 20 sessions of the following regimens: Group
16 A (control group): manual lymphatic drainage + Intermittent Pneumatic Compression +
17 Bandages; Group B: pneumatic lymphatic drainage + Intermittent Pneumatic Compression
18 + Bandages; and Group C: only Intermittent Pneumatic Compression + Bandages. The
19 outcome was the percentage reduction in excess volume (PREV). Results demonstrated
20 that all patients improved after treatment. Global mean of PREV was 63.9%, without
21 significant differences between the groups. Most frequent adverse events were discomfort
22 and lymphangitis, without differences between groups. A greater baseline edema, an upper-
23 limb lymphedema and a history of dermatolymphangitis were independent predictive
24 factors of worse response in the multivariate analysis. Authors concluded that decongestive
25 lymphatic therapy performed only with intermittent pneumatic compression plus bandages
26 is not inferior to the traditional trimodal therapy with manual lymphatic drainage. This
27 approach did not increase adverse events.

28
29 Corum et al. (2021) compared the effects of CDT accompanied by resistance exercises on
30 extremity circumference, lymphedema volume, grip strength, functional status, and quality
31 of life in the treatment of breast cancer-related lymphedema (BCRL) in patients with and
32 without pain. Fifty patients with unilateral BCRL were divided into groups: with pain
33 (Group 1, $n = 25$) and without pain (Group 2, $n = 25$). Thirty minutes of manual lymphatic
34 drainage and multilayered short-stretch bandaging were applied to all patients five times a
35 week for 4 weeks. In addition, all patients were informed about skin care and given a
36 supervised resistance exercise program throughout the treatment. During the 1-month
37 follow-up period, patients were asked to use low-tension elastic garments and to continue
38 their home exercise program. Differences in upper extremity circumference and volume;
39 grip strength; Quick Disabilities of the Arm, Shoulder, and Hand; and Functional
40 Assessment of Cancer Therapy-Breast scores were evaluated at baseline, after treatment
41 (week 4), and at 1-month follow-up. Moreover, the pain intensity of patients in Group 1
42 was measured using the visual analog scale (VAS). Patients in both Group 1 and Group 2

1 showed a statistical improvement in all outcome measures after treatment and at follow-up
2 ($p < 0.05$); however, no significant difference was observed between the groups ($p > 0.05$).
3 In Group 1, a statistically significant decrease was observed in the VAS score both at the
4 end of treatment and at 1-month follow-up ($p < 0.05$). Authors concluded that combined
5 CDT and resistance exercises appear to be effective in BCRL patients both with and
6 without pain.

7
8 McNeely et al. (2022) examined the efficacy of nighttime compression as a self-
9 management strategy for women with chronic breast cancer-related lymphedema. Authors
10 conducted a parallel 3-arm, multicenter, randomized trial. Women were recruited from 3
11 centers in Canada and randomized to group 1 (daytime compression garment alone
12 [standard care]), group 2 (daytime compression garment plus nighttime compression
13 bandaging), or group 3 (daytime compression garment plus the use of a nighttime
14 compression system garment). The primary outcome was the change in excess arm volume
15 from the baseline to 12 weeks. Participants from all groups used a nighttime compression
16 system garment from weeks 13 to 24. One hundred twenty women were enrolled, 118
17 completed the randomized trial, and 114 completed the 24-week follow-up. The rates of
18 adherence to nighttime compression were $95\% \pm 15\%$ and $96\% \pm 11\%$ in the compression
19 bandaging and nighttime compression system groups, respectively. After the intervention,
20 the addition of nighttime compression was found to be superior to standard care for both
21 absolute milliliter reductions ($P = .006$) and percentage reductions ($P = .002$) in excess arm
22 lymphedema volume. Significant within-group changes were seen for quality of life across
23 all groups; however, no between-group differences were found ($P > .05$). Authors
24 concluded that this study demonstrated a significant improvement in arm lymphedema
25 volume from the addition of nighttime compression whether through the application of
26 compression bandaging or through the use of a nighttime compression system garment.

27
28 De Vrieze et al. (2022) investigated the effect of fluoroscopy-guided manual lymphatic
29 drainage (MLD) versus traditional MLD or placebo MLD for the treatment of breast
30 cancer-related lymphoedema (BCRL) when added to decongestive lymphatic therapy
31 (DLT). All participants received standard DLT (education, skin care, compression therapy
32 and exercises). Participants were randomized to also receive fluoroscopy guided MLD
33 ($n = 65$), traditional MLD ($n = 64$) or placebo MLD ($n = 65$). Participants received
34 14 sessions of physiotherapy during the 3-week intensive phase and 17 sessions during the
35 6-month maintenance phase. Participants performed self-management on the other days.
36 All outcomes were measured: at baseline; after the intensive phase; after 1, 3 and 6 months
37 of maintenance phase; and after 6 months of follow-up. The primary outcomes were
38 reduction in excess volume of the arm/hand and accumulation of excess volume at the
39 shoulder/trunk, with the end of the intensive phase as the primary endpoint. Excess
40 lymphoedema volume decreased after 3 weeks of intensive treatment in each group. The
41 effect of fluoroscopy guided MLD was very similar to traditional MLD and placebo MLD.

1 Authors concluded that in patients with chronic BCRL, MLD did not provide clinically
2 important additional benefit when added to other components of DLT.

3
4 Borman et al. (2022) evaluated the effects of CDT in patients with breast cancer-related
5 lymphedema (BCRL), in regard to volume reduction, functional status and QoL. Fifty
6 patients with unilateral BCRL were included. All patients received combined phase 1 CDT
7 including skincare, manual lymphatic drainage, multilayer bandaging and supervised
8 exercises, 5 times a week for 3 weeks, as a total of 15 sessions. Patients were assessed by
9 limb volumes and excess volumes. The functional disability was evaluated by quick
10 disability of arm, shoulder and hand questionnaire (Q-DASH). QoL was assessed by the
11 European Organization for Research and Treatment of Cancer Core Cancer Quality of Life
12 Questionnaire (EORTC QLQ-C30) and its breast-cancer-module (EORTC QLQ-BR23).
13 Fifty females with mean age of 53.22 ± 11.2 years were included. The median duration of
14 lymphedema was 12 months. There were 22 patients in stage1, 26 in stage2 and 2 patients
15 in stage3. The mean baseline limb and excess volumes were significantly decreased at the
16 end of therapies. The Q-DASH and EORTC QLQ-C30 and BR23 scores were also
17 decreased significantly. The improvements in volumes were related negatively with the
18 duration of lymphedema, and the stage of lymphedema. Authors concluded that CDT in a
19 combined manner performed daily for 3 weeks, greatly reduces the volumes as well as
20 improves the disability and QoL, especially when performed earlier.

21
22 De Sire et al. (2022) completed a review to characterize the comprehensive management
23 of lymphedema, providing a broad overview of the potential therapy available in the
24 current literature. They conclude that a multidisciplinary treatment should be truly
25 integrated for lymphedema patients, and rehabilitation should be considered the
26 cornerstone of the multidisciplinary treatment not only for patients not suitable for surgical
27 interventions but also before and after surgical procedures. Rehabilitation should include
28 (CDT), which includes manual lymph drainage (MLD), skin care, specialized exercises,
29 compression garments and self-education. Rangon et al. (2022) investigated the immediate,
30 short-term, and long-term effects of complex physical therapy and multimodal approaches
31 on lymphedema secondary to breast cancer. Fourteen studies were identified for the
32 systematic review and 11 studies for the meta-analysis. The common outcomes involved
33 total volume, pain, and physical function of the upper limb. Complex physical therapy has
34 shown a favorable tendency to control outcomes in the short- and long-term. The meta-
35 analysis indicated a small effect for volume reduction and a moderate effect for short-term
36 pain reduction. Authors concluded that high-quality evidence suggests a more significant
37 effect of complex physical therapy on multimodal approaches to the control of the upper
38 limb total volume, substantiating the absence of changes in the current clinical practice in
39 the management of lymphedema secondary to breast cancer. Future research should aim to
40 identify concrete effect of therapeutic modalities in the immediate-, short-, and long-term.

1 Lin et al. (2022) analyzed the effectiveness of manual lymphatic drainage (MLD) in breast
 2 cancer-related lymphedema (BCRL) patients in a systematic review and meta-analysis. In
 3 total, 11 RCTs involving 1564 patients were included, in which 10 trials were deemed
 4 viable for inclusion in the meta-analysis. Due to the effects of MLD for BCRL, statistically
 5 significant improvements were found on the incidence of lymphedema and pain intensity.
 6 Besides, the meta-analysis carried out implied that the effects that MLD had on volumetric
 7 changes of lymphedema and quality of life, were not statistically significant. The current
 8 evidence based on the RCTs shows that pain of BCRL patients undergoing MLD is
 9 significantly improved, while our findings do not support the use of MLD in improving
 10 volumetric of lymphedema and quality of life. Torgbenu et al. (2023) aimed to describe
 11 and compare international guidelines on lymphedema diagnosis, assessment, and
 12 management. This systematic review of 1,564 articles and 159 web pages yielded 14
 13 guidelines. All guidelines were from high-income countries. Ten focused exclusively on
 14 lymphedema, and four on cancer. Most (n = 13) guidelines recommended an integrated
 15 medical, psychological assessment, and physical examination, with a limb volume
 16 measurement of >10% in the affected limb compared, confirming a lymphedema diagnosis.
 17 Recommended management involved Complex Decongestive Therapy (CDT) followed by
 18 self-management using skincare, self-lymphatic drainage massage, exercise, and
 19 compression.

20 **Other Treatments**

21 **Low Level Laser Therapy (LLLT)**

22 Carati et al. (2003) performed a double blind, placebo controlled randomized, single
 23 crossover trial use of low-level laser therapy (LLLT) for a treatment option for patients
 24 with post mastectomy lymphedema (PML). Participants received either one cycle or two
 25 cycles of LLLT to the axillary region of their affected arm. The authors monitored for
 26 reduction in affected limb volume, upper body extracellular tissue fluid distribution, dermal
 27 tonometry and range of motion. The result yielded two cycles of LLLT improved
 28 lymphedema; however, limb volume reduction was not immediate and was reported two
 29 to three (2-3) months post-treatment (Carati et al., 2003). A study conducted by
 30 Dirican et al. (2011) reviewed the authors' short-term experience with low-level laser
 31 therapy in the treatment of breast-cancer related lymphedema. Treatment consisted of laser
 32 therapy using 300mJ for one minute to 17 different points on the surgical scar tissue of
 33 the axilla. Patients were also treated with compression garments or bandaging.
 34 Two of the patients in the study also had sessions using an intermittent
 35 compression device. Authors concluded that patients with breast cancer gain additional
 36 benefits in the form of volume reduction from low level laser therapy when used in
 37 conjunction with other standard treatments (Dirican et al., 2011). Further studies are needed
 38 to confirm these findings. Smoot et al. (2015) examined the literature on effectiveness of
 39 LLLT in reducing limb volume and pain in adults with breast cancer related lymphedema
 40 (BCRL). They concluded that moderate strength evidence supports LLLT in the
 41 management of BCRL. The overall review of literature investigated conservative therapies
 42

1 for secondary arm lymphedema that can be divided into intensive treatments administered
2 by trained healthcare professionals and limb maintenance that are carried out by the patient.
3 Treatments that are predominantly administered by healthcare professionals, such as
4 CDT, MLD, and pneumatic pump therapy generally yielded the larger reduction in limb
5 volume. LLLT may be a potential treatment option, but more well-designed studies are
6 needed. Maintenance therapies generally carried out by the patient in a self-care
7 program (e.g., wearing compression garments, performing limb exercises, limb
8 elevation, and self-massage) yielded smaller limb reduction.

9
10 Kozanoglu et al. (2022) investigated the long-term effectiveness of combined intermittent
11 pneumatic compression (IPC) plus low-level laser therapy (LLLT) versus IPC therapy
12 alone in patients with postmastectomy upper limb lymphedema (PML). The patients were
13 allocated into two groups in this single-blinded, controlled clinical trial. Group I received
14 combined treatment with IPC plus LLLT ($n = 21$) and group II received only IPC ($n = 21$).
15 IPC treatment was given 5 sessions per week for 4 weeks (20 sessions). LLLT was also
16 performed 5 sessions per week for 4 weeks (20 sessions). Clinical evaluations were
17 performed before and after the treatment at the 3, 6, and 12-month follow-up visits.
18 According to within-group analysis, statistically significant improvements in the
19 circumference difference and grip strength were observed in both groups. Visual analog
20 scale values for arm pain and shoulder pain during motion were decreased only in group I.
21 Authors concluded that interventions have positive effects on lymphedema, grip strength,
22 and pain. Long-term effects of combined therapy, especially on pain, are slightly superior
23 to the pneumatic compression alone.

24
25 Wang et al. (2022) analyzed the evidence from existing systematic reviews investigating
26 the effectiveness and safety of low-level laser therapy (LLLT) in patients with breast
27 cancer-related lymphedema (BCRL). Conflicting results regarding the effectiveness of
28 LLLT were presented by the overview of systematic reviews. The AMSTAR 2 showed that
29 the methodological quality of included systematic reviews was low or critically low quality
30 due to one or more critical weaknesses. The GRADE and GRADE-CERQual showed that
31 the evidence quality was low to very low for most outcomes. The updated systematic
32 review showed that LLLT may offer additional benefits as compared to compression
33 therapies (pneumatic compression or compression bandage), placebo laser, or no treatment
34 for patients with BCRL. However, when compared to other types of active interventions,
35 LLLT did not improve outcomes significantly. None of the treatment-related adverse event
36 was reported. Many trials had a high or unclear risk of bias for two or more items, and this
37 updated systematic review showed low quality of evidence per outcome using GRADE
38 approach. Due to insufficient data and poor quality of evidence, there is uncertain evidence
39 to reach these conclusions that LLLT is superior to another active or negative intervention
40 and is safe. More RCTs of high methodological quality, with large sample sizes and long-
41 term follow-up, are needed to inform clinical guidelines and routine practice.

1 Qiao et al. (2023) analyzed the efficacy of MLD for BCRL. A total of 457 patients were
 2 included in the analysis. There was no significant difference in the amount of upper
 3 extremity edema between the MLD treatment and control or no MLD groups. However,
 4 when the treatment course was ≥ 20 sessions, there was a significant reduction in the upper
 5 extremity volume. There was also a significant reduction in the upper extremity volume
 6 when treatment duration was > 2 weeks. Authors concluded that manual lymphatic drainage
 7 treatment statistically did not reduce the upper extremity limb volume of BCRL, but upper
 8 extremity volume was reduced at statistically significant levels when treatment number
 9 were ≥ 20 sessions or the duration of treatment was > 2 weeks.

10 **Exercise**

11 Kwan et al. (2011) conducted a systematic review of the contemporary literature to distill
 12 the weight of the evidence and provide recommendations for exercise and lymphedema
 13 care in breast cancer survivors. Seven studies were identified addressing resistance
 14 exercise, seven studies on aerobic and resistance exercise, and five studies on other exercise
 15 modalities. Studies concluded that slowly progressive exercise of varying modalities is not
 16 associated with the development or exacerbation of breast cancer-related lymphedema and
 17 can be safely pursued with proper supervision. Combined aerobic and resistance exercise
 18 appear safe, but confirmation requires larger and more rigorous studies. Authors concluded
 19 that strong evidence is now available on the safety of resistance exercise without an
 20 increase in risk of lymphedema for breast cancer patients. Buchan et al. (2016) compared
 21 the effect of progressive resistance- or aerobic-based exercise on breast cancer-related
 22 lymphedema extent and severity, as well as participants' muscular strength and endurance,
 23 aerobic fitness, body composition, upper-body function and QoL. Authors concluded that
 24 participating in resistance- or aerobic-based exercise did not change lymphedema status
 25 but led to clinically relevant improvements in function and QoL, with findings suggesting
 26 that neither mode is superior with respect to lymphoedema impact. As such, personal
 27 preferences, survivorship concerns and functional needs are important and
 28 relevant considerations when prescribing exercise mode to those with secondary
 29 lymphedema.
 30

31
 32 Overall, the consensus of managing lymphedema includes an appropriate diagnosis based
 33 on the patient's history and physical examination and a determination that there
 34 is consistent evidence to indicate that lymphedema can be reliably measured
 35 using circumferential measures or volume displacement. Complex decongestive
 36 therapy is suggested as the main method of conservative care for lymphedema and is a
 37 combination of therapies that includes manual lymphatic drainage (MLD), application of
 38 compression low stretch bandages, skin care, education, and exercise. Johansson et al.
 39 (2015) reported on the evidence-based or traditional treatment of cancer-related
 40 lymphedema. Authors concluded that with accumulating evidence and experience, it is
 41 time to consider if altering these treatment principles is needed. Based on accumulating
 42 evidence, authors suggest less emphasis on manual lymph drainage and more on early

1 diagnosis, compression, weight control and exercise for improvement of strength and
2 circulation. Bakar and Tuğral (2017) reviewed the current management strategies for lower
3 extremity management of lymphedema after gynecologic cancer surgery. Studies indicated
4 that the incidence of lower extremity lymphedema ranges between 2.4% and 41% after
5 pelvic lymph node dissection in patients with gynecologic malignancies. Thus,
6 management of lower extremity lymphedema in patients after gynecologic cancer surgery
7 is an important issue. Complex decongestive therapy method is still the gold standard of
8 lymphedema management.

9
10 Nelson (2017) summarizes the results of recent randomized controlled trials (RCTs)
11 investigating the effect of resistance exercise in those with, or at risk for, BCRL. He also
12 wanted to determine whether breast cancer survivors can perform RET at sufficient
13 intensities to elicit gains in strength without causing BCRL flare-up or incidence. A total
14 of 6 RCTs, involving 805 breast cancer survivors, met the inclusion criteria and
15 corresponded to the aims of this review. The results of this review indicated that breast
16 cancer survivors can perform RET at high-enough intensities to elicit strength gains
17 without triggering changes to lymphedema status. There is strong evidence indicating that
18 RET produces significant gains in muscular strength without provoking BCRL. Do et al.
19 (2017) investigated the effects of a complex rehabilitation (CR) program and complex
20 decongestive therapy (CDT) on edema status, physical function, and quality of life in
21 patients with unilateral lower-limb lymphedema after gynecologic cancer surgery. CR
22 comprised of stretching, strengthening, and aerobic exercises was performed for 40min,
23 five times a week for 4weeks. Intensive CDT was administered by a physical therapist
24 during weeks 0-2 and by the patients themselves during weeks 2-4. Results demonstrated
25 that the edema status, fatigue, pain, and GCLQ-K scores were significantly improved in
26 both groups after the 4-week intervention. Physical function and fatigue and the 30-s chair
27 stand test and quadriceps muscle strength were significantly improved in the CRCDT
28 group compared with the CDT alone group. Authors concluded that CR improves physical
29 function, fatigue, and muscular strength without increasing edema status in patients with
30 unilateral lower-limb lymphedema after gynecologic cancer surgery. Yeung et al. (2018)
31 conducted a systematic review and meta-analysis on aquatic therapy compared to other
32 lymphedema interventions. Four RCTs of moderate quality were included. There was
33 moderate level evidence of no significant short-term differences in lymphedema status
34 (relative volume) between patients receiving aquatic lymphatic therapy compared to land
35 based standard care. There was low level evidence that no significant difference between
36 aquatic lymphatic therapy and standard care for improving upper limb physical function.
37 Authors conclude that current evidence indicates no significant benefit of aquatic
38 lymphatic therapy over standard land-based care for treatment of lymphedema. Further
39 research is needed to strengthen the evidence.

40
41 Baumann et al. (2018) assessed the effect of different types of exercise on breast cancer-
42 related lymphedema (BCRL) in order to understand the role of exercise in this patient

1 group. Eleven randomized controlled trials that included 458 women with breast cancer in
 2 aftercare were included. The different types of exercise consisted of aqua lymph training,
 3 swimming, resistance exercise, yoga, aerobic, and gravity-resistive exercise. Four of the
 4 studies measured a significant reduction in BCRL status based on arm volume and seven
 5 studies reported significant subjective improvements. No study showed adverse effects of
 6 exercise on BCRL. Authors concluded that the evidence indicates that exercise can
 7 improve subjective and objective parameters in BCRL patients, with dynamic, moderate,
 8 and high-frequency exercise appearing to provide the most positive effects. Hasenoehrl et
 9 al. (2020) performed a systematic review analyzing resistance exercise (RE) intervention
 10 trials in breast cancer survivors (BCS) regarding their effect on breast cancer-related
 11 lymphedema (BCRL) status. Authors concluded that RE seems to be a safe exercise
 12 intervention for BCS and not to be harmful concerning the risk of lymphedema.
 13 Lymphedema assessment methods that allow for a qualitative analysis of arm tissue
 14 composition should be favored. At the current time breast cancer related lymphedema is
 15 incurable but well manageable by a number of physical therapy modalities, especially
 16 complete decongestive therapy (CDT). One of the encouraging treatment methods is
 17 resistance exercise.

18
 19 Kilbreath et al. (2020) investigated whether an exercise program reduced breast
 20 lymphoedema symptoms compared to a non-exercise control group. This single-blinded
 21 randomized controlled trial was conducted in which women with stable breast
 22 lymphoedema ($n = 89$) were randomized into an exercise ($n = 41$) or control ($n = 47$) group.
 23 The intervention comprised a 12-week combined aerobic and resistance training program,
 24 supervised weekly by an accredited exercise physiologist. All participants completed a
 25 weekly symptoms diary and were assessed monthly to ensure that there was no
 26 exacerbation of their lymphoedema. Changes in the breast were captured physically with
 27 ultrasound and bioimpedance spectroscopy and changes in symptoms were captured using
 28 European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer
 29 (BR23) and Lymphoedema Symptom Intensity and Distress questionnaires. The exercise
 30 group reported a greater reduction in breast-related symptoms than the control group,
 31 assessed by the EORTC BR23 breast symptom questions. Measures of extracellular fluid,
 32 assessed with bioimpedance spectroscopy ratio, decreased in the exercise group compared
 33 to the control group. No significant difference was detected in dermal thickness in the
 34 breast, assessed by ultrasound. Session attendance in the exercise sessions was high, with
 35 two musculoskeletal adverse events reported, but no exacerbations of lymphoedema
 36 observed. Authors concluded that combined resistance and aerobic exercise training is safe
 37 for women living with breast lymphoedema. Preliminary data suggest exercise training can
 38 reduce breast lymphoedema symptoms to a greater extent than usual care.

39
 40 Saraswathi et al. (2021) systematically reviewed the effect of yoga therapy on managing
 41 lymphedema, increasing the range of motion (ROM), and quality of life (QoL) among
 42 breast cancer survivors. Studies which assessed the outcome variables such as QoL and

1 management of lymphedema or related physical symptoms as effect of yoga intervention
2 were considered for review. The different styles of yoga employed in the studies were
3 Iyengar yoga ($n = 2$), Satyananda yoga ($n = 2$), Hatha yoga ($n = 2$), and Ashtanga yoga
4 ($n = 1$). The length of intervention and post intervention analysis ranged from 8 weeks to
5 12 months. Authors concluded that yoga could be a safe and feasible exercise intervention
6 for BCRL patients. Evidence generated from these studies was of moderate strength.
7 Further long-term clinical trials with large sample size are essential for the development
8 and standardization of yoga intervention guidelines for BCRL patients.

9
10 Bruce et al. (2021) evaluated whether a structured exercise programme improved
11 functional and health related quality of life outcomes compared with usual care for women
12 at high risk of upper limb disability after breast cancer surgery. Subjects included 392
13 women undergoing breast cancer surgery, at risk of postoperative upper limb morbidity,
14 randomised (1:1) to usual care with structured exercise ($n=196$) or usual care alone
15 ($n=196$). Usual care (information leaflets) only or usual care plus a physiotherapy led
16 exercise programme, incorporating stretching, strengthening, physical activity, and
17 behavioural change techniques to support adherence to exercise, introduced at 7-10 days
18 postoperatively, with two further appointments at one and three months. Main outcome
19 measures included the Disability of Arm, Hand and Shoulder (DASH) questionnaire at 12
20 months, analysed by intention to treat. Secondary outcomes included DASH subscales,
21 pain, complications, health related quality of life, and resource use, from a health and
22 personal social services perspective. Upper limb function improved after exercise
23 compared with usual care for exercise. Secondary outcomes favoured exercise over usual
24 care, with lower pain intensity at 12 months and fewer arm disability symptoms at 12
25 months. No increase in complications, lymphoedema, or adverse events was noted in
26 participants allocated to exercise. Exercise accrued lower costs per patient and was cost
27 effective compared with usual care. Authors concluded that the PROSPER exercise
28 programme was clinically effective and cost effective and reduced upper limb disability
29 one year after breast cancer treatment in patients at risk of treatment related postoperative
30 complications.

31
32 Corum et al. (2021) compared the effects of complex decongestive therapy (CDT)
33 accompanied by resistance exercises on extremity circumference, lymphedema volume,
34 grip strength, functional status, and quality of life in the treatment of breast cancer-related
35 lymphedema (BCRL) in patients with and without pain. Fifty patients with unilateral
36 BCRL were divided into groups: with pain (Group 1, $n = 25$) and without pain (Group 2, n
37 $= 25$). Thirty minutes of manual lymphatic drainage and multilayered short-stretch
38 bandaging were applied to all patients five times a week for 4 weeks. In addition, all
39 patients were informed about skin care and given a supervised resistance exercise program
40 throughout the treatment. During the 1-month follow-up period, patients were asked to use
41 low-tension elastic garments and to continue their home exercise program. Differences in
42 upper extremity circumference and volume; grip strength; Quick Disabilities of the Arm,

1 Shoulder, and Hand; and Functional Assessment of Cancer Therapy-Breast scores were
2 evaluated at baseline, after treatment (week 4), and at 1-month follow-up. Moreover, the
3 pain intensity of patients in Group 1 was measured using the visual analog scale (VAS).
4 Patients in both Group 1 and Group 2 showed a statistical improvement in all outcome
5 measures after treatment and at follow-up ($p < 0.05$); however, no significant difference
6 was observed between the groups ($p > 0.05$). In Group 1, a statistically significant decrease
7 was observed in the VAS score both at the end of treatment and at 1-month follow-up ($p <$
8 0.05). Authors concluded that combined CDT and resistance exercises appear to be
9 effective in BCRL patients both with and without pain.

10
11 Hayes et al. (2022) evaluated the effects of exercise on (i) the prevention of cancer-related
12 lymphedema (CRL), and (ii) the treatment of CRL, lymphedema-associated symptoms,
13 and other health outcomes among individuals with CRL in a systematic review and meta-
14 analysis. Twelve studies ($n = 1,955$; 75% moderate-high quality) and 36 studies ($n = 1,741$;
15 58% moderate-high quality) were included in the prevention and treatment aim,
16 respectively. Relative risk of developing CRL for those in the exercise group compared
17 with the non-exercise group was 0.90 overall, and 0.49 for those with 5 or more lymph
18 nodes removed. Improvements post-intervention were observed for pain, upper-body
19 function and strength, lower-body strength, fatigue and quality of life for those in the
20 exercise group. Authors concluded that findings support the application of exercise
21 guidelines for the wider cancer population to those with or at risk of CRL. This includes
22 promotion of aerobic and resistance exercise, and not just resistance exercise alone, as well
23 as unsupervised exercise guided by symptom response.

24
25 Maccarone et al. (2023) evaluated the effects of water-based exercise on pain, limb motor
26 function, quality of life (QoL), and limb volume among patients affected by primary and
27 secondary upper and lower limb lymphedema. The search produced a total of 88 studies.
28 Eight randomized controlled trials and one clinical study of patients with primary or
29 secondary lymphedema of upper or lower limbs who had undergone water-based treatment
30 were included in the present study. Most trials had focused on breast cancer-related
31 lymphedema. The shoulder range of flexion, external rotation, and abduction have been
32 shown to improve after performing a water-based exercise protocol. Some evidence has
33 also demonstrated that the lymphedematous limb strength can improve. Moreover, water-
34 based exercise seemed to improve pain perception and QoL for patients with upper or lower
35 limb lymphedema. In contrast, in the control groups, the QoL showed a tendency to worsen
36 over time. Although some studies had not reported beneficial effects on the
37 lymphedematous limb volume, most of the studies examined had reported a reduction in
38 volume, especially in the short term. No adverse events were reported in the included
39 studies. Authors concluded that these findings from the present review have shown the
40 potential for aquatic exercise in lymphedema management. However, at the same time, the
41 findings underline the multiple limitations resulting from the heterogeneity in the study
42 populations and related physical activity protocols. The role of aquatic exercise in the

1 conservative treatment of lymphedema requires further investigation in the future to define
2 specific protocols of application.

4 **Measurement of Lymphedema**

5 Hidding et al. (2016) attempted to provide best evidence of which measurement
6 instruments are most appropriate in measuring lymphedema in its different stages. Authors
7 concluded that measurement instruments with evidence for good reliability and validity are
8 Bioelectrical Impedance Spectroscopy (BIS), water volumetry, tape measurement and
9 perometry, where BIS can detect alterations in extracellular fluid in stage 1 lymphedema
10 and the other measurement instruments alterations in volume starting from stage 2. In
11 research water volumetry is indicated as reference test for measuring lymphedema in upper
12 extremities. Limitations included the following: no uniform definition of lymphedema was
13 available and a gold standard as reference test was lacking. Items concerning risk of bias
14 were study design, patient selection, description of lymphedema, blinding of test outcomes
15 and number of included patients.

17 **PRACTITIONER SCOPE AND TRAINING**

18 Practitioners should practice only in the areas in which they are competent based on their
19 education, training and experience. Levels of education, experience, and proficiency may
20 vary among individual practitioners. It is ethically and legally incumbent on a practitioner
21 to determine where they have the knowledge and skills necessary to perform such services
22 and whether the services are within their scope of practice.

24 It is best practice for the practitioner to appropriately render services to a member only if
25 they are trained, equally skilled, and adequately competent to deliver a service compared
26 to others trained to perform the same procedure. If the service would be most competently
27 delivered by another health care practitioner who has more skill and training, it would be
28 best practice to refer the member to the more expert practitioner.

30 Best practice can be defined as a clinical, scientific, or professional technique, method, or
31 process that is typically evidence-based and consensus driven and is recognized by a
32 majority of professionals in a particular field as more effective at delivering a particular
33 outcome than any other practice (Joint Commission International Accreditation Standards
34 for Hospitals, 2020).

36 Depending on the practitioner's scope of practice, training, and experience, a member's
37 condition and/or symptoms during examination or the course of treatment may indicate the
38 need for referral to another practitioner or even emergency care. In such cases it is prudent
39 for the practitioner to refer the member for appropriate co-management (e.g., to their
40 primary care physician) or if immediate emergency care is warranted, to contact 911 as
41 appropriate. See the *Managing Medical Emergencies (CPG 159 – S)* clinical practice
42 guideline for information.

1 **References**

- 2 Ahmed Omar, M. T., Abd-El-Gayed Ebid, A., & El Morsy, A. M. (2011). Treatment of
 3 post-mastectomy lymphedema with laser therapy: double blind placebo control
 4 randomized study. *The Journal of surgical research*, 165(1), 82–90.
 5 <https://doi.org/10.1016/j.jss.2010.03.050>
 6
- 7 Andersen, L., Højris, I., Erlandsen, M., & Andersen, J. (2000). Treatment of breast-cancer-
 8 related lymphedema with or without manual lymphatic drainage--a randomized
 9 study. *Acta oncologica (Stockholm, Sweden)*, 39(3), 399–405.
 10 <https://doi.org/10.1080/028418600750013186>
 11
- 12 Badger, C., Preston, N., Seers, K., & Mortimer, P. (2004). Physical therapies for reducing
 13 and controlling lymphoedema of the limbs. *The Cochrane database of systematic
 14 reviews*, (4), CD003141. <https://doi.org/10.1002/14651858.CD003141.pub2>
 15
- 16 Bakar, Y., & Tuğral, A. (2017). Lower Extremity Lymphedema Management after
 17 Gynecologic Cancer Surgery: A Review of Current Management Strategies. *Annals of
 18 vascular surgery*, 44, 442–450. <https://doi.org/10.1016/j.avsg.2017.03.197>
 19
- 20 Baumann FT, Reike A, Reimer V, Schumann M, Hallek M, Taaffe DR, Newton RU,
 21 Galvao DA. Effects of physical exercise on breast cancer-related secondary
 22 lymphedema: a systematic review. *Breast Cancer Res Treat*. 2018 Jul;170(1):1-13
 23
- 24 Baxter GD, Liu L, Petrich S, Gisselman AS, Chapple C, Anders JJ, Tumilty S. Low level
 25 laser therapy (Photobiomodulation therapy) for breast cancer-related lymphedema: a
 26 systematic review. *BMC Cancer*. 2017 Dec 7;17(1):833
 27
- 28 Białoszewski, D., Woźniak, W., & Zarek, S. (2009). Clinical efficacy of kinesiology taping
 29 in reducing edema of the lower limbs in patients treated with the ilizarov method--
 30 preliminary report. *Ortopedia, traumatologia, rehabilitacja*, 11(1), 46–54
 31
- 32 Bicego, D., Brown, K., Ruddick, M., Storey, D., Wong, C., & Harris, S. R. (2006). Exercise
 33 for women with or at risk for breast cancer-related lymphedema. *Physical
 34 therapy*, 86(10), 1398–1405. <https://doi.org/10.2522/ptj.20050328>
 35
- 36 Borman P, Yaman A, Yasrebi S, Pınar İnanlı A, Arıkan Dönmez A. Combined Complete
 37 Decongestive Therapy Reduces Volume and Improves Quality of Life and Functional
 38 Status in Patients With Breast Cancer-Related Lymphedema. *Clin Breast Cancer*.
 39 2022;22(3):e270-e277. doi:10.1016/j.clbc.2021.08.005

- 1 Bosman J. (2014). Lymph taping for lymphoedema: an overview of the treatment and its
 2 uses. *British journal of community nursing, Suppl*, S12–S18.
 3 <https://doi.org/10.12968/bjcn.2014.19.sup4.s12>
 4
- 5 Buchan, J., Janda, M., Box, R., Schmitz, K., & Hayes, S. (2016). A Randomized Trial on
 6 the Effect of Exercise Mode on Breast Cancer-Related Lymphedema. *Medicine and
 7 science in sports and exercise*, 48(10), 1866–1874.
 8 <https://doi.org/10.1249/MSS.0000000000000988>
 9
- 10 Canadian Agency for Drugs and Technologies in Health (CADTH). Health Technology
 11 Inquiry Service. (2010). Manual lymph drainage or intermittent pneumatic
 12 compression for adult patients with secondary lymphedema: clinical effectiveness.
 13 Health Technology Assessment. Accessed May 25, 2023 from
 14 https://www.cadth.ca/sites/default/files/pdf/k0173_lymphedema_htis-L1-5.pdf
 15
- 16 Canadian Agency for Drugs and Technologies in Health (CADTH). Health Technology
 17 Inquiry Service. (2011). Compression Garments for the Treatment of Primary and
 18 Secondary Lymphedema: Clinical Effectiveness and Guidelines. Accessed May 25,
 19 2023 from [https://www.cadth.ca/sites/default/files/pdf/htis/oct-2011/RB0437-
 20 000%20Lymphedema.pdf](https://www.cadth.ca/sites/default/files/pdf/htis/oct-2011/RB0437-000%20Lymphedema.pdf)
 21
- 22 Carati, C. J., Anderson, S. N., Gannon, B. J., & Piller, N. B. (2003). Treatment of
 23 postmastectomy lymphedema with low-level laser therapy: a double blind, placebo-
 24 controlled trial. *Cancer*, 98(6), 1114–1122. <https://doi.org/10.1002/cncr.11641>
 25
- 26 Casley-Smith, J. R., Boris, M., Weindorf, S., & Lasinski, B. (1998). Treatment for
 27 lymphedema of the arm--the Casley-Smith method: a noninvasive method produces
 28 continued reduction. *Cancer*, 83(12 Suppl American), 2843–2860.
 29 [https://doi.org/10.1002/\(sici\)1097-0142\(19981215\)83:12b+<2843::aid-
 31 cncr38>3.3.co;2-l](https://doi.org/10.1002/(sici)1097-0142(19981215)83:12b+<2843::aid-

 30 cncr38>3.3.co;2-l)
 31
- 32 Centers for Medicare and Medicaid (CMS) Services. Billing and Coding: High
 33 Compression Bandage System Clarification (A53287). Retrieved on May 25, 2023
 34 from [https://www.cms.gov/medicare-coverage-
 36 database/view/article.aspx?articleid=53287](https://www.cms.gov/medicare-coverage-

 35 database/view/article.aspx?articleid=53287)
 36
- 37 Cheifetz, O., Haley, L., & Breast Cancer Action (2010). Management of secondary
 38 lymphedema related to breast cancer. *Canadian family physician Medecin de famille
 39 canadien*, 56(12), 1277–1284
 40
- 41 Cormier, J. N., Askew, R. L., Mungovan, K. S., Xing, Y., Ross, M. I., & Armer, J. M.
 42 (2010). Lymphedema beyond breast cancer: a systematic review and meta-analysis of

1 cancer-related secondary lymphedema. *Cancer*, 116(22), 5138–5149.
 2 <https://doi.org/10.1002/cncr.25458>

3

4 Corum M, Basoglu C, Korkmaz MD, Yildirim MA, Ones K. Effectiveness of Combined
 5 Complex Decongestive Therapy and Resistance Exercises in the Treatment of
 6 Lymphedema Associated with Breast Cancer and the Effect of Pain on Treatment
 7 Response. *Lymphat Res Biol*. 2021;19(4):383-390. doi:10.1089/lrb.2020.0099

8

9 Dayes, I. S., Whelan, T. J., Julian, J. A., Parpia, S., Pritchard, K. I., D'Souza, D. P.,
 10 Kligman, L., Reise, D., LeBlanc, L., McNeely, M. L., Manchul, L., Wiernikowski, J.,
 11 & Levine, M. N. (2013). Randomized trial of decongestive lymphatic therapy for the
 12 treatment of lymphedema in women with breast cancer. *Journal of clinical oncology :*
 13 *official journal of the American Society of Clinical Oncology*, 31(30), 3758–3763.
 14 <https://doi.org/10.1200/JCO.2012.45.7192>

15

16 Devoogdt, N., Van Kampen, M., Geraerts, I., Coremans, T., & Christiaens, M. R. (2010).
 17 Different physical treatment modalities for lymphoedema developing after axillary
 18 lymph node dissection for breast cancer: a review. *European journal of obstetrics,*
 19 *gynecology, and reproductive biology*, 149(1), 3–9

20

21 De Vrieze T, Gebruers N, Nevelsteen I, et al. Manual lymphatic drainage with or without
 22 fluoroscopy guidance did not substantially improve the effect of decongestive
 23 lymphatic therapy in people with breast cancer-related lymphoedema (EForT-BCRL
 24 trial): a multicentre randomised trial. *J Physiother*. 2022;68(2):110-122.
 25 doi:10.1016/j.jphys.2022.03.010

26

27 Didem, K., Ufuk, Y. S., Serdar, S., & Zümre, A. (2005). The comparison of two different
 28 physiotherapy methods in treatment of lymphedema after breast surgery. *Breast cancer*
 29 *research and treatment*, 93(1), 49–54

30

31 Dirican, A., Andacoglu, O., Johnson, R., McGuire, K., Mager, L., & Soran, A. (2011). The
 32 short-term effects of low-level laser therapy in the management of breast-cancer-
 33 related lymphedema. *Supportive care in cancer : official journal of the Multinational*
 34 *Association of Supportive Care in Cancer*, 19(5), 685–690.
 35 <https://doi.org/10.1007/s00520-010-0888-8>

36

37 Do, J. H., Choi, K. H., Ahn, J. S., & Jeon, J. Y. (2017). Effects of a complex rehabilitation
 38 program on edema status, physical function, and quality of life in lower-limb
 39 lymphedema after gynecological cancer surgery. *Gynecologic oncology*, 147(2), 450–
 40 455. <https://doi.org/10.1016/j.ygyno.2017.09.003>

- 1 Executive Committee (2016). The Diagnosis and Treatment of Peripheral Lymphedema:
 2 2016 Consensus Document of the International Society of
 3 Lymphology. *Lymphology*, 49(4), 170–184
 4
- 5 Executive Committee of the International Society of Lymphology. The diagnosis and
 6 treatment of peripheral lymphedema: 2020 Consensus Document of the International
 7 Society of Lymphology. *Lymphology* 2020, 53, 3–19
 8
- 9 Ezzo, J., Manheimer, E., McNeely, M. L., Howell, D. M., Weiss, R., Johansson, K. I., Bao,
 10 T., Bily, L., Tuppo, C. M., Williams, A. F., & Karadibak, D. (2015). Manual lymphatic
 11 drainage for lymphedema following breast cancer treatment. The Cochrane database of
 12 systematic reviews, (5), CD003475.
 13 <https://doi.org/10.1002/14651858.CD003475.pub2>
 14
- 15 Finnane, A., Janda, M., & Hayes, S. C. (2015). Review of the evidence of lymphedema
 16 treatment effect. *American journal of physical medicine & rehabilitation*, 94(6), 483–
 17 498. <https://doi.org/10.1097/PHM.0000000000000246>
 18
- 19 Földi E. (1998). The treatment of lymphedema. *Cancer*, 83(12 Suppl American), 2833–
 20 2834. [https://doi.org/10.1002/\(sici\)1097-0142\(19981215\)83:12b+<2833::aid-](https://doi.org/10.1002/(sici)1097-0142(19981215)83:12b+<2833::aid-cncr35>3.0.co;2-3)
 21 [cncr35>3.0.co;2-3](https://doi.org/10.1002/(sici)1097-0142(19981215)83:12b+<2833::aid-cncr35>3.0.co;2-3)
 22
- 23 Forner-Cordero I, Muñoz-Langa J, DeMiguel-Jimeno JM, Rel-Monzó P. Physical
 24 therapies in the decongestive treatment of lymphedema: A randomized, non-inferiority
 25 controlled study. *Clin Rehabil*. 2021;35(12):1743-1756.
 26 [doi:10.1177/02692155211032651](https://doi.org/10.1177/02692155211032651)
 27
- 28 Fu, Mei R et al. “Putting evidence into practice: cancer-related lymphedema.” *Clinical*
 29 *journal of oncology nursing* vol. 18 Suppl (2014): 68-79. [doi:10.1188/14.CJON.S3.68-](https://doi.org/10.1188/14.CJON.S3.68-79)
 30 [79](https://doi.org/10.1188/14.CJON.S3.68-79)
 31
- 32 Gatt, M., Willis, S., & Leuschner, S. (2017). A meta-analysis of the effectiveness and safety
 33 of kinesiology taping in the management of cancer-related lymphoedema. *European*
 34 *journal of cancer care*, 26(5), 10.1111/ecc.12510
 35
- 36 Golshan, M., & Smith, B. (2006). Prevention and management of arm lymphedema in the
 37 patient with breast cancer. *The journal of supportive oncology*, 4(8), 381–386
 38
- 39 Haghigat, S., Lotfi-Tokaldany, M., Yunesian, M., Akbari, M. E., Nazemi, F., & Weiss, J.
 40 (2010). Comparing two treatment methods for post mastectomy lymphedema: complex
 41 decongestive therapy alone and in combination with intermittent pneumatic
 42 compression. *Lymphology*, 43(1), 25–33

- 1 Hamner, J. B., & Fleming, M. D. (2007). Lymphedema therapy reduces the volume of
 2 edema and pain in patients with breast cancer. *Annals of surgical oncology*, 14(6),
 3 1904–1908. <https://doi.org/10.1245/s10434-006-9332-1>
 4
- 5 Harris, S. R., Hugi, M. R., Olivotto, I. A., Levine, M., & Steering Committee for Clinical
 6 Practice Guidelines for the Care and Treatment of Breast Cancer (2001). *Clinical
 7 practice guidelines for the care and treatment of breast cancer: 11.
 8 Lymphedema. CMAJ : Canadian Medical Association journal = journal de
 9 l'Association medicale canadienne*, 164(2), 191–199
 10
- 11 Hasenoehrl T, Keilani M, Palma S, Crevenna R. Resistance exercise and breast cancer
 12 related lymphedema - a systematic review update. *Disabil Rehabil.* 2020 Jan;42(1):26-
 13 35
 14
- 15 Hayes SC, Singh B, Reul-Hirche H, et al. The Effect of Exercise for the Prevention and
 16 Treatment of Cancer-related Lymphedema: A Systematic Review with Meta-analysis
 17 [published online ahead of print, 2022 Mar 22]. *Med Sci Sports Exerc.*
 18 2022;10.1249/MSS.0000000000002918
 19
- 20 Hidding, J. T., Viehoff, P. B., Beurskens, C. H., van Laarhoven, H. W., Nijhuis-van der
 21 Sanden, M. W., & van der Wees, P. J. (2016). Measurement Properties of Instruments
 22 for Measuring of Lymphedema: Systematic Review. *Physical therapy*, 96(12), 1965–
 23 1981. <https://doi.org/10.2522/ptj.20150412>
 24
- 25 Hwang, J. M., Hwang, J. H., Kim, T. W., Lee, S. Y., Chang, H. J., & Chu, I. H. (2013).
 26 Long-term effects of complex decongestive therapy in breast cancer patients with arm
 27 lymphedema after axillary dissection. *Annals of rehabilitation medicine*, 37(5), 690–
 28 697
 29
- 30 International Society of Lymphology (2003). The diagnosis and treatment of peripheral
 31 lymphedema. Consensus document of the International Society of
 32 Lymphology. *Lymphology*, 36(2), 84–91
 33
- 34 International Society of Lymphology (2009). The diagnosis and treatment of peripheral
 35 lymphedema. 2009 Consensus Document of the International Society of
 36 Lymphology. *Lymphology*, 42(2), 51–60
 37
- 38 International Society of Lymphology. The diagnosis and treatment of peripheral
 39 lymphedema. Consensus document of the International Society of Lymphology. 2020.
 40 Retrieved on May 25, 2023 from [https://isl.arizona.edu/sites/default/files/2021-
 41 09/Consensus%20Document-SM.pdf](https://isl.arizona.edu/sites/default/files/2021-09/Consensus%20Document-SM.pdf)

- 1 Johansson, K., Karlsson, K., & Nikolaidis, P. (2015). Evidence-based or traditional
2 treatment of cancer-related lymphedema. *Lymphology*, 48(1), 24–27
3
- 4 Kalemikerakis I, Evaggelakou A, Kavga A, Vastardi M, Konstantinidis T, Govina O.
5 Diagnosis, treatment and quality of life in patients with cancer-related lymphedema. *J*
6 *BUON*. 2021;26(5):1735-1741
7
- 8 Kalron, A., & Bar-Sela, S. (2013). A systematic review of the effectiveness of Kinesio
9 Taping--fact or fashion?. *European journal of physical and rehabilitation*
10 *medicine*, 49(5), 699–709
11
- 12 Karadibak, D., Yavuzsen, T., & Saydam, S. (2008). Prospective trial of intensive
13 decongestive physiotherapy for upper extremity lymphedema. *Journal of surgical*
14 *oncology*, 97(7), 572–577. <https://doi.org/10.1002/jso.21035>
15
- 16 Kärki, A., Anttila, H., Tasmuth, T., & Rautakorpi, U. M. (2009). Lymphoedema therapy
17 in breast cancer patients: a systematic review on effectiveness and a survey of current
18 practices and costs in Finland. *Acta oncologica (Stockholm, Sweden)*, 48(6), 850–859.
19 <https://doi.org/10.1080/02841860902755251>
20
- 21 Kasseroller R. G. (1998). The Vodder School: the Vodder method. *Cancer*, 83(12 Suppl
22 *American)*, 2840–2842.
23
- 24 Kilbreath SL, Ward LC, Davis GM, Degnim AC, Hackett DA, Skinner TL, Black D.
25 Reduction of breast lymphoedema secondary to breast cancer: a randomised controlled
26 exercise trial. *Breast Cancer Res Treat*. 2020 Nov;184(2):459-467. doi:
27 10.1007/s10549-020-05863-4
28
- 29 Kim, D. S., Sim, Y. J., Jeong, H. J., & Kim, G. C. (2010). Effect of active resistive exercise
30 on breast cancer-related lymphedema: a randomized controlled trial. *Archives of*
31 *physical medicine and rehabilitation*, 91(12), 1844–1848.
32 <https://doi.org/10.1016/j.apmr.2010.09.008>
33
- 34 Kim, S. J., & Park, Y. D. (2008). Effects of complex decongestive physiotherapy on the
35 oedema and the quality of life of lower unilateral lymphoedema following treatment
36 for gynecological cancer. *European journal of cancer care*, 17(5), 463–468.
37 <https://doi.org/10.1111/j.1365-2354.2007.00877.x>
38
- 39 Kligman, L., Wong, R. K., Johnston, M., & Laetsch, N. S. (2004). The treatment of
40 lymphedema related to breast cancer: a systematic review and evidence
41 summary. *Supportive care in cancer : official journal of the Multinational Association*

- 1 of Supportive Care in Cancer, 12(6), 421–431. [https://doi.org/10.1007/s00520-004-](https://doi.org/10.1007/s00520-004-0627-0)
 2 0627-0
 3
- 4 Koul, R., Dufan, T., Russell, C., Guenther, W., Nugent, Z., Sun, X., & Cooke, A. L. (2007).
 5 Efficacy of complete decongestive therapy and manual lymphatic drainage on
 6 treatment-related lymphedema in breast cancer. *International journal of radiation*
 7 *oncology, biology, physics*, 67(3), 841–846.
 8 <https://doi.org/10.1016/j.ijrobp.2006.09.024>
 9
- 10 Kozanoglu, E., Basaran, S., Paydas, S., & Sarpel, T. (2009). Efficacy of pneumatic
 11 compression and low-level laser therapy in the treatment of postmastectomy
 12 lymphoedema: a randomized controlled trial. *Clinical rehabilitation*, 23(2), 117–124.
 13 <https://doi.org/10.1177/0269215508096173>
 14
- 15 Kozanoglu E, Gokcen N, Basaran S, Paydas S. Long-Term Effectiveness of Combined
 16 Intermittent Pneumatic Compression Plus Low-Level Laser Therapy in Patients with
 17 Postmastectomy Lymphedema: A Randomized Controlled Trial. *Lymphat Res Biol*.
 18 2022;20(2):175-184. doi:10.1089/lrb.2020.0132
 19
- 20 Kwan, M. L., Cohn, J. C., Armer, J. M., Stewart, B. R., & Cormier, J. N. (2011). Exercise
 21 in patients with lymphedema: a systematic review of the contemporary
 22 literature. *Journal of cancer survivorship : research and practice*, 5(4), 320–336.
 23 <https://doi.org/10.1007/s11764-011-0203-9>
 24
- 25 Lasinski B. B. (2013). Complete decongestive therapy for treatment of
 26 lymphedema. *Seminars in oncology nursing*, 29(1), 20–27.
 27 <https://doi.org/10.1016/j.soncn.2012.11.004>
 28
- 29 Lasinski B.B. Boris M. (2002). Comprehensive lymphedema management: results of a 5
 30 year follow-up. *Lymphology*,35 (suppl):301-4
 31
- 32 Lasinski, B. B., McKillip Thrift, K., Squire, D., Austin, M. K., Smith, K. M., Wanchai, A.,
 33 Green, J. M., Stewart, B. R., Cormier, J. N., & Armer, J. M. (2012). A systematic
 34 review of the evidence for complete decongestive therapy in the treatment of
 35 lymphedema from 2004 to 2011. *PM & R : the journal of injury, function, and*
 36 *rehabilitation*, 4(8), 580–601. <https://doi.org/10.1016/j.pmrj.2012.05.003>
 37
- 38 Lawenda, B. D., Mondry, T. E., & Johnstone, P. A. (2009). Lymphedema: a primer on the
 39 identification and management of a chronic condition in oncologic treatment. *CA: a*
 40 *cancer journal for clinicians*, 59(1), 8–24. <https://doi.org/10.3322/caac.20001>

- 1 Leal, N. F., Carrara, H. H., Vieira, K. F., & Ferreira, C. H. (2009). Physiotherapy treatments
2 for breast cancer-related lymphedema: a literature review. *Revista latino-americana de*
3 *enfermagem*, 17(5), 730–736. <https://doi.org/10.1590/s0104-11692009000500021>
4
- 5 Leung, E. Y., Tirlapur, S. A., & Meads, C. (2015). The management of secondary lower
6 limb lymphoedema in cancer patients: a systematic review. *Palliative medicine*, 29(2),
7 112–119. <https://doi.org/10.1177/0269216314545803>
8
- 9 Lin Y, Yang Y, Zhang X, Li W, Li H, Mu D. Manual Lymphatic Drainage for Breast
10 Cancer-related Lymphedema: A Systematic Review and Meta-analysis of Randomized
11 Controlled Trials. *Clin Breast Cancer*. 2022;22(5):e664-e673.
12 [doi:10.1016/j.clbc.2022.01.013](https://doi.org/10.1016/j.clbc.2022.01.013)
13
- 14 Maccarone MC, Venturini E, Menegatti E, Giancesini S, Masiero S. Water-based exercise
15 for upper and lower limb lymphedema treatment. *J Vasc Surg Venous Lymphat Disord*.
16 2023;11(1):201-209. [doi:10.1016/j.jvsv.2022.08.002](https://doi.org/10.1016/j.jvsv.2022.08.002)
17
- 18 Macdonald, J. M., Sims, N., & Mayrovitz, H. N. (2003). Lymphedema, lipedema, and the
19 open wound: the role of compression therapy. *The Surgical clinics of North*
20 *America*, 83(3), 639–658. [https://doi.org/10.1016/S0039-6109\(02\)00201-3](https://doi.org/10.1016/S0039-6109(02)00201-3)
21
- 22 McNeely, M. L., Magee, D. J., Lees, A. W., Bagnall, K. M., Haykowsky, M., & Hanson,
23 J. (2004). The addition of manual lymph drainage to compression therapy for breast
24 cancer related lymphedema: a randomized controlled trial. *Breast cancer research and*
25 *treatment*, 86(2), 95–106. <https://doi.org/10.1023/B:BREA.0000032978.67677.9f>
26
- 27 McNeely ML, Dolgoy ND, Rafn BS, et al. Nighttime compression supports improved self-
28 management of breast cancer-related lymphedema: A multicenter randomized
29 controlled trial. *Cancer*. 2022;128(3):587-596. [doi:10.1002/cncr.33943](https://doi.org/10.1002/cncr.33943)
30
- 31 Megens, A., & Harris, S. R. (1998). Physical therapist management of lymphedema
32 following treatment for breast cancer: a critical review of its effectiveness. *Physical*
33 *therapy*, 78(12), 1302–1311. <https://doi.org/10.1093/ptj/78.12.1302>
34
- 35 Michopoulos E, Papathanasiou G, Vasilopoulos G, Polikandrioti M, Dimakakos E.
36 Effectiveness and Safety of Complete Decongestive Therapy of Phase I: A
37 Lymphedema Treatment Study in the Greek Population. *Cureus*. 2020 Jul
38 19;12(7):e9264. [doi: 10.7759/cureus.9264](https://doi.org/10.7759/cureus.9264)
39
- 40 Mondry, T. E., Riffenburgh, R. H., & Johnstone, P. A. (2004). Prospective trial of complete
41 decongestive therapy for upper extremity lymphedema after breast cancer

- 1 therapy. *Cancer journal* (Sudbury, Mass.), 10(1), 42–19.
 2 <https://doi.org/10.1097/00130404-200401000-00009>
 3
- 4 Morris, D et al. “The clinical effects of Kinesio® Tex taping: A systematic
 5 review.” *Physiotherapy theory and practice* vol. 29,4 (2013): 259-70.
 6 doi:10.3109/09593985.2012.731675
 7
- 8 Moseley, A. L., Carati, C. J., & Piller, N. B. (2007). A systematic review of common
 9 conservative therapies for arm lymphoedema secondary to breast cancer
 10 treatment. *Annals of oncology : official journal of the European Society for Medical*
 11 *Oncology*, 18(4), 639–646. <https://doi.org/10.1093/annonc/mdl182>
 12
- 13 National Cancer Institute (NCI). Lymphedema [Physician Data Query (PDQ®)]. Last
 14 Modified: 2019. Retrieved on May 25, 2023 from
 15 [http://www.cancer.gov/cancertopics/pdq/supportivecare/lymphedema/healthprofessio](http://www.cancer.gov/cancertopics/pdq/supportivecare/lymphedema/healthprofessional/AllPages)
 16 [nal/AllPages](http://www.cancer.gov/cancertopics/pdq/supportivecare/lymphedema/healthprofessional/AllPages)
 17
- 18 National Lymphedema Network (NLN). Position statement of the national lymphedema
 19 network. *The Diagnosis And Treatment Of Lymphedema*. February 2011. Currently
 20 under review and revision. Retrieved on June 13, 2022 from
 21 [https://13gkfrf50081srbm42cuf1bf-wp-](https://13gkfrf50081srbm42cuf1bf-wpengine.netdna-ssl.com/wp-content/uploads/2016/02/2011_NLN_Position-Statement-of-NLN.pdf)
 22 [engine.netdna-ssl.com/wp-](https://13gkfrf50081srbm42cuf1bf-wpengine.netdna-ssl.com/wp-content/uploads/2016/02/2011_NLN_Position-Statement-of-NLN.pdf)
 23 [content/uploads/2016/02/2011_NLN_Position-Statement-of-NLN.pdf](https://13gkfrf50081srbm42cuf1bf-wpengine.netdna-ssl.com/wp-content/uploads/2016/02/2011_NLN_Position-Statement-of-NLN.pdf)
 24
- 24 Nelson NL. Breast Cancer-Related Lymphedema and Resistance Exercise: A Systematic
 25 Review. *J Strength Cond Res*. 2016 Sep;30(9):2656-65
 26
- 27 Oremus, M., Dayes, I., Walker, K., & Raina, P. (2012). Systematic review: conservative
 28 treatments for secondary lymphedema. *BMC cancer*, 12, 6.
 29 <https://doi.org/10.1186/1471-2407-12-6>
 30
- 31 Oremus, M., Walker, K., Dayes, I., & Raina, P. (2010). Diagnosis and Treatment of
 32 Secondary Lymphedema. Agency for Healthcare Research and Quality (US)
 33
- 34 Pekyavaş, N. Ö., Tunay, V. B., Akbayrak, T., Kaya, S., & Karataş, M. (2014). Complex
 35 decongestive therapy and taping for patients with postmastectomy lymphedema: a
 36 randomized controlled study. *European journal of oncology nursing : the official*
 37 *journal of European Oncology Nursing Society*, 18(6), 585–590.
 38 <https://doi.org/10.1016/j.ejon.2014.06.010>
 39
- 40 Petrek, J. A., Pressman, P. I., & Smith, R. A. (2000). Lymphedema: current issues in
 41 research and management. *CA: a cancer journal for clinicians*, 50(5), 292–311.
 42 <https://doi.org/10.3322/canjclin.50.5.292>

- 1 Poage, E., Singer, M., Armer, J., Poundall, M., & Shellabarger, M. J. (2008). Demystifying
 2 lymphedema: development of the lymphedema putting evidence into practice
 3 card. *Clinical journal of oncology nursing*, 12(6), 951–964.
 4 <https://doi.org/10.1188/08.CJON.951-964>
 5
- 6 Qiao J, Yang LN, Kong YH, Huang X, Li Y, Bai DQ. Effect of Manual Lymphatic
 7 Drainage on Breast Cancer-Related Postmastectomy Lymphedema: A Meta-analysis
 8 of Randomized Controlled Trials. *Cancer Nurs.* 2023;46(2):159-166.
 9 doi:10.1097/NCC.0000000000001061
 10
- 11 Rangon FB, da Silva J, Dibai-Filho AV, Guirro RRJ, Guirro ECO. Effects of Complex
 12 Physical Therapy and Multimodal Approaches on Lymphedema Secondary to Breast
 13 Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
 14 *Arch Phys Med Rehabil.* 2022;103(2):353-363
 15
- 16 Ridner S. H. (2002). Breast cancer lymphedema: pathophysiology and risk reduction
 17 guidelines. *Oncology nursing forum*, 29(9), 1285–1293.
 18 <https://doi.org/10.1188/02.ONF.1285-1293>
 19
- 20 Ryans K, Perdomo M, Davies CC, Levenhagen K, Gilchrist L. Rehabilitation interventions
 21 for the management of breast cancer-related lymphedema: developing a patient-
 22 centered, evidence-based plan of care throughout survivorship. *J Cancer Surviv.*
 23 2023;17(1):237-245. doi:10.1007/s11764-021-00991-2
 24
- 25 Saraswathi, V., Latha, S., Niraimathi, K., & Vidhubala, E. (2021). Managing
 26 Lymphedema, Increasing Range of Motion, and Quality of Life through Yoga Therapy
 27 among Breast Cancer Survivors: A Systematic Review. *International journal of*
 28 *yoga*, 14(1), 3–17. https://doi.org/10.4103/ijoy.IJOY_73_19
 29
- 30 Sezgin Ozcan, D., Dalyan, M., Unsal Delialioglu, S., Duzlu, U., Polat, C. S., & Koseoglu,
 31 B. F. (2018). Complex Decongestive Therapy Enhances Upper Limb Functions in
 32 Patients with Breast Cancer-Related Lymphedema. *Lymphatic research and*
 33 *biology*, 16(5), 446–452. <https://doi.org/10.1089/lrb.2017.0061>
 34
- 35 Shao, Y., Qi, K., Zhou, Q. H., & Zhong, D. S. (2014). Intermittent pneumatic compression
 36 pump for breast cancer-related lymphedema: a systematic review and meta-analysis of
 37 randomized controlled trials. *Oncology research and treatment*, 37(4), 170–174.
 38 <https://doi.org/10.1159/000360786>
 39
- 40 Smoot, B., Chiavola-Larson, L., Lee, J., Manibusan, H., & Allen, D. D. (2015). Effect of
 41 low-level laser therapy on pain and swelling in women with breast cancer-related

- 1 lymphedema: a systematic review and meta-analysis. *Journal of cancer survivorship : research and practice*, 9(2), 287–304. <https://doi.org/10.1007/s11764-014-0411-1>
- 2
3
- 4 Stout Gergich, N. L., Pfalzer, L. A., McGarvey, C., Springer, B., Gerber, L. H., & Soballe, P. (2008). Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. *Cancer*, 112(12), 2809–2819. <https://doi.org/10.1002/cncr.23494>
- 5
6
7
- 8 Szolnoky, G., Lakatos, B., Keskeny, T., Varga, E., Varga, M., Dobozy, A., & Kemény, L. (2009). Intermittent pneumatic compression acts synergistically with manual lymphatic drainage in complex decongestive physiotherapy for breast cancer treatment-related lymphedema. *Lymphology*, 42(4), 188–194
- 9
10
11
12
- 13 Szuba, A., Cooke, J. P., Yousuf, S., & Rockson, S. G. (2000). Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema. *The American journal of medicine*, 109(4), 296–300. [https://doi.org/10.1016/s0002-9343\(00\)00503-9](https://doi.org/10.1016/s0002-9343(00)00503-9)
- 14
15
16
- 17 Thompson, B., Gaitatzis, K., Janse de Jonge, X., Blackwell, R., & Koelmeyer, L. A. (2021). Manual lymphatic drainage treatment for lymphedema: a systematic review of the literature. *Journal of cancer survivorship : research and practice*, 15(2), 244–258. <https://doi.org/10.1007/s11764-020-00928-1>
- 18
19
20
21
- 22 Torgbenu E, Luckett T, Buhagiar MA, Phillips JL. Guidelines Relevant to Diagnosis, Assessment, and Management of Lymphedema: A Systematic Review. *Adv Wound Care (New Rochelle)*. 2023;12(1):15-27. doi:10.1089/wound.2021.0149
- 23
24
25
- 26 Torres Lacomba, M., Yuste Sánchez, M. J., Zapico Goñi, A., Prieto Merino, D., Mayoral del Moral, O., Cerezo Téllez, E., & Minayo Mogollón, E. (2010). Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. *BMJ (Clinical research ed.)*, 340, b5396
- 27
28
29
30
- 31 Torres-Lacomba, M., Navarro-Brazález, B., Prieto-Gómez, V., Ferrandez, J. C., Bouchet, J. Y., & Romay-Barrero, H. (2020). Effectiveness of four types of bandages and kinesiotope for treating breast-cancer-related lymphoedema: a randomized, single-blind, clinical trial. *Clinical rehabilitation*, 34(9), 1230–1241. <https://doi.org/10.1177/0269215520935943>
- 32
33
34
35
36
- 37 Tsai, H. J., Hung, H. C., Yang, J. L., Huang, C. S., & Tsauo, J. Y. (2009). Could Kinesio tape replace the bandage in decongestive lymphatic therapy for breast-cancer-related lymphedema? A pilot study. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*, 17(11), 1353–1360. <https://doi.org/10.1007/s00520-009-0592-8>
- 38
39
40
41

- 1 Tunkel, R. S., & Lachmann, E. (1998). Lymphedema of the limb. An overview of treatment
2 options. *Postgraduate medicine*, 104(4), . <https://doi.org/10.3810/pgm.1998.10.450>
3
- 4 Vignes, S., Blanchard, M., Arrault, M., & Porcher, R. (2013). Intensive complete
5 decongestive physiotherapy for cancer-related upper-limb lymphedema: 11 days
6 achieved greater volume reduction than 4. *Gynecologic oncology*, 131(1), 127–130.
7 <https://doi.org/10.1016/j.ygyno.2013.07.101>
8
- 9 Vignes, S., Porcher, R., Arrault, M., & Dupuy, A. (2007). Long-term management of breast
10 cancer-related lymphedema after intensive decongestive physiotherapy. *Breast cancer*
11 *research and treatment*, 101(3), 285–290. <https://doi.org/10.1007/s10549-006-9297-6>
12
- 13 Wang Y, Ge Y, Xing W, et al. The effectiveness and safety of low-level laser therapy on
14 breast cancer-related lymphedema: An overview and update of systematic reviews.
15 *Lasers Med Sci.* 2022;37(3):1389-1413. doi:10.1007/s10103-021-03446-3
16
- 17 Watanabe, Y., Koshiyama, M., Seki, K., Nakagawa, M., Ikuta, E., Oowaki, M., &
18 Sakamoto, S. I. (2019). Development and Themes of Diagnostic and Treatment
19 Procedures for Secondary Leg Lymphedema in Patients with Gynecologic
20 Cancers. *Healthcare* (Basel, Switzerland), 7(3), 101.
21 <https://doi.org/10.3390/healthcare7030101>
22
- 23 Yeung W, Semciw AI. Aquatic Therapy for People with Lymphedema: A Systematic
24 Review and Meta-analysis. *Lymphat Res Biol.* 2018 Feb;16(1):9-19
25
- 26 Zasadzka, E., Trzmiel, T., Kleczewska, M., & Pawlaczyk, M. (2018). Comparison of the
27 effectiveness of complex decongestive therapy and compression bandaging as a
28 method of treatment of lymphedema in the elderly. *Clinical interventions in aging*, 13,
29 929–934. <https://doi.org/10.2147/CIA.S159380>
30
- 31 Zuther E. and Norton, S. (2013). *Pathology. Lymphedema Management: The*
32 *Comprehensive Guide for Practitioners* (3rd ed). Theime Medical Publishers, Inc.